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Abstract
Pharmaceutical companies accrued fines of over $30 billion within 25 years because of
noncompliance with regulations. Noncompliance with regulations results in fines and an
adverse impact on company profitability. Some pharmaceutical company managers lack
effective strategies to ensure overall company compliance with regulation. Based on
complexity leadership theory, the purpose of this single case study was to explore
strategies pharmaceutical company managers used to ensure compliance with regulatory
requirements in Nigeria. The target population was functional managers purposely
selected because they had successfully implemented strategies for compliance with the
regulatory requirements in Nigeria. Data were collected through face-to-face and
telephone interviews with 4 company managers and from company records, regulatory
documents, and websites. Analysis of data involved using computer-assisted qualitative
data analysis tools and content analysis to code and identify patterns and themes.
Findings revealed 3 prominent themes: establishment of regulatory affairs unit and
engaged leadership; hiring of qualified of employees, training, and continuous learning;
and strategies to navigate through barriers to enhance regulatory compliance. The
implications for positive social change lie in the availability of affordable pharmaceutical
products with implications for the overall health of communities. Compliance with
regulatory requirements helps to ensure that pharmaceutical companies develop high
quality and safe products, which are critical in healthcare leading to the prevention and
cure of diseases, which will ultimately improve and save people’s lives.

Strategies for Compliance with Government Regulation in a Pharmaceutical Company
by
Charles Jagun

MS, North Carolina Central University, 2010
BS, University of Ilorin, 1989

Doctoral Study Submitted in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Business Administration

Walden University
July 2018

Dedication
First, I dedicate my study to Christ, my provider, my source of inspiration, and the
very present help in time of need. Second, to my family, Moji, Efi, and Uje for their love
and support, who have encouraged me in my unending search for knowledge. To my
mom, dad, brothers, and sisters for their fervent prayers. Finally, to my close friends who
encouraged me to remain steadfast during the study.

Acknowledgments
I wish to express my sincere gratitude to my doctoral study committee chair, Dr.
Gergana Velkova who brings out the excellence in others for her support and mentorship.
Thank you, Dr. Velkova for your emails, conference calls, and suggestions for making
me a better scholar and comfortable in every aspect of the research process. I would like
to thank my other doctoral study committee members, Dr. Robert Hockin (SCM) and Dr.
Scott Burus (URR), for their suggestions and positive feedback. The work of other
faculty members and Walden University Writing Center editors cannot be measured, and
I want to thank them for helping whenever help is needed. Thanks to my family (Moji,
Efi, and Uje), for their understanding, while in this program. Finally, I appreciate the
contribution of friends and other family members for their encouragement all through the
DBA program.

Table of Contents
List of Figures .................................................................................................................... iv
Section 1: Foundation of the Study......................................................................................1
Background of the Problem ...........................................................................................1
Problem Statement .........................................................................................................2
Purpose Statement ..........................................................................................................3
Nature of the Study ........................................................................................................3
Research Question .........................................................................................................5
Interview Questions .......................................................................................................5
Conceptual Framework ..................................................................................................6
Operational Definitions ..................................................................................................7
Assumptions, Limitations, and Delimitations ................................................................7
Assumptions............................................................................................................ 7
Limitations .............................................................................................................. 8
Delimitations ........................................................................................................... 8
Significance of the Study ...............................................................................................9
Contribution to Business Practice ........................................................................... 9
Implications for Social Change ............................................................................. 10
A Review of the Professional and Academic Literature ..............................................10
Complexity Leadership Theory ............................................................................ 11
Supporting and Rival Theories ............................................................................. 24
The Pharmaceutical Industry ................................................................................ 38
i

Transition .....................................................................................................................54
Section 2: The Project ........................................................................................................55
Purpose Statement ........................................................................................................55
Role of the Researcher .................................................................................................56
Participants ...................................................................................................................59
Research Method and Design ......................................................................................60
Research Method .................................................................................................. 61
Research Design.................................................................................................... 63
Population and Sampling .............................................................................................66
Ethical Research...........................................................................................................68
Data Collection Instruments ........................................................................................69
Data Collection Technique ..........................................................................................72
Data Organization Technique ......................................................................................75
Data Analysis ...............................................................................................................75
Reliability and Validity ................................................................................................78
Reliability.............................................................................................................. 78
Validity ................................................................................................................. 79
Transition and Summary ..............................................................................................81
Section 3: Application to Professional Practice and Implications for Change ..................82
Introduction ..................................................................................................................82
Presentation of the Findings.........................................................................................83
Applications to Professional Practice ........................................................................113
ii

Implications for Social Change ..................................................................................114
Recommendations for Action ....................................................................................116
Recommendations for Further Research ....................................................................117
Reflections .................................................................................................................118
Conclusion .................................................................................................................120
References ........................................................................................................................122
Appendix A: Interview Protocol ......................................................................................156
Appendix B: Invitation Letter ..........................................................................................159
Appendix C: NIH Certificate ...........................................................................................161

iii

List of Figures
Figure 1 Overview of the regulatory processes in pharmaceutical licensing ....................50
Figure 2 Typical drug approval procedure in the United States ........................................51

iv

1
Section 1: Foundation of the Study
Compliance with regulations is critical to business performance and assurance of
safety and product performance in the pharmaceutical industry (Ding, Eliashberg, &
Stremersch, 2014; Proches & Bodhanya, 2015). In recent years, regulatory
noncompliance in the pharmaceutical industry is on the rise and is becoming a challenge
to company leaders and managers (Page, Cyr, & Richardson, 2015). Wang, Zheng, Ren,
and Sun (2016) found that the U.S. Food and Drug Administration issued 997 warning
letters to medical products manufacturers in specific areas of the manufacturing process
during 2007 to 2014. The regulatory requirements for pharmaceutical products are always
evolving, a condition that presents an ongoing challenge to managers in pharmaceutical
organizations (Thach, 2015). Noncompliance with regulations results in huge fines and a
significant amount of settlement with a considerable impact on company image and
profitability (Mulinari, 2016). Having a strategy in place to ensure personnel compliance
with regulation is critical to the avoidance of the adverse impact of noncompliance in the
sector (Sabel, Herrigel, & Kristensen, 2017).
Background of the Problem
The increasing number of litigations and violation citations in the pharmaceutical
industry are indications of widespread problems with business operations in the sector
(Rodwin, 2015). As regulation becomes precise, encompassing, and complex, reports of
increasing incidence of noncompliance is on the rise because of rising costs and lack of
knowledge of regulations (Lemmens & Gibson, 2014). Nielsen and Parker (2012) noted

2
that despite the importance of compliance with regulations, not much is known about
companies’ compliance with regulations.
Complying with regulations requires personnel knowledge and understanding of
regulations to avoid violation or noncompliance (Mendoza, Dekker, & Wielhouwer,
2016). Nielsen and Parker (2012) rationalized that motivation is vital in the consideration
of the topic of regulatory compliance in companies. As such, company personnel have
different motivations to ensure compliance with regulations, meaning that the attitude of
personnel to compliance is dependent on several factors including customers, capital,
skills, technologies, trade associations, and communities (Lynch-Wood & Williamson,
2014).
The increase in noncompliance and the resulting impact on pharmaceutical
companies resulted in the need for an effective strategy to ensure managers and
subordinates take steps that lead to overall compliance as they perform critical roles in
the product lifecycle (Arora, Christman, Mays, & Schmidt, 2013). Herzberg (2015)
posited that several factors are involved in personnel motivation, and a greater
understanding and application of those factors results in the desired outcome. Further
research on regulatory compliance strategies in pharmaceutical companies is necessary to
provide pharmaceutical managers strategies that other managers in pharmaceutical
companies used to ensure compliance with regulatory requirements.
Problem Statement
Noncompliance with government regulations in the pharmaceutical industry is on
the rise and impacts pharmaceutical companys’ profitability (Page et al., 2015). The US
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FDA reported a 64% increase in the number of current Good Manufacturing Practice
(cGMP) noncompliance from 2007 to in 2012 (Wang, Zheng, Ren, & Sun, 2016).
Almashat, Wolfe, and Carome (2016) found that pharmaceutical companies paid over
$30 billion over 25 years for various violations in the United States with the resultant
impact on company profit. The general business problem is that noncompliance with
regulation has a negative impact on company revenue, brand value, product development,
product approval, and a number of regulatory investigations. The specific business
problem is that some pharmaceutical company managers lack strategies to ensure
compliance with regulatory requirements.
Purpose Statement
The purpose of this qualitative single case study was to explore strategies that
managers in pharmaceutical companies use to ensure compliance with regulatory
requirements. The target population for this study consisted of 4 pharmaceutical
managers in a Nigerian pharmaceutical company who successfully implemented
strategies for compliance with the regulatory requirements in Nigeria. The implications
for social change include the potential to improve the abilities of managers to ensure
compliance in a regulated environment, which might lead to increased access,
availability, and affordability of pharmaceutical products by individuals with limited
access to good healthcare.
Nature of the Study
I used the qualitative research method in this study. A qualitative method allows a
researcher to study a phenomenon in depth using open-ended questions that enable
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researchers to discover new, rich, and nuanced phenomena based on participants’
experiences (De Massis & Kotlar, 2014; Yin, 2014). Researchers in qualitative research
focus on perceptions and experiences taken from only a few representative participants;
hence, researchers cannot generalize the outcome of a study to a population (Starman,
2013). I used the qualitative method to explore and understand the strategies used by the
research participants to ensure compliance with regulatory requirements.
The quantitative method is not suitable for studying participants’ experiences or
nuanced phenomena; rather, it involves data collection through sampling or experiments
to test hypothesis, analyze data using statistical or mathematical forms, and the results are
generalizable (Bernard, 2013; Brockington, 2014). Mixed methods, a combination of
both quantitative and qualitative research (Dumbili, 2014), was not suitable for this study
because I did not test or build theories.
I selected a qualitative single case study design for this study. Scholars use case
study to gather in-depth information and enable review and examination of a bounded
system involving a real-life phenomenon (Morse & McEnvoy, 2014; Yin, 2014). A case
study methodology was most appropriate for this study. Case study is a strategy available
to researchers for studying topics with relatively few previous studies (Yin, 2014). In
addition, researchers use ethnographic or phenomenological design in qualitative
business research (Yin, 2014). In an ethnographic study, the researcher studies beliefs,
the way of life, and culture of a group of people through observation or participation
(Ferguson, 2016). Ethnographic approach was not suitable for this study because my
focus was not on the culture of the people. In phenomenology, the researcher examines
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lived experiences of individuals to understand the root meaning of a phenomenon (Gill,
2014). I did not select phenomenology for this study because I did not seek to explore
lived experiences of those experiencing a phenomenon. I concluded that case study
approach would be appropriate for this study because I explored the strategies used by
managers in a single pharmaceutical company to ensure compliance with regulatory
requirements.
Research Question
The research question for this study was the following: What strategies do
pharmaceutical company managers use to ensure compliance with regulatory
requirements.
Interview Questions
1.

What is your role in ensuring compliance with government regulations in

your company?
2.

What strategies do you use to prevent noncompliance with government

regulations?
3.

How do you communicate regulatory requirements within your company?

4.

What specific strategies do you use to ensure regulatory compliance?

5.

What challenges do you encounter in implementing strategies for compliance

with regulatory requirements?
6.

How do you address the challenges to the implementation of strategies for

noncompliance with government regulations?
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7.

How do you assess the effectiveness of your strategies to prevent

noncompliance?
8.

What other relevant information about compliance with regulatory

requirements can you provide?
Conceptual Framework
The theory that I used as the conceptual framework of this study was the
complexity leadership theory. Marion and Uhl-Bien developed the complexity leadership
paradigm in 2001 (Marion & Uhl-Bien, 2001). Uhl-Bien, Marion, and McKelvey (2007)
extended the works on complexity leadership by addressing complex interactive
dynamics from which adaptive outcomes emerge. Uhl-Bien et al. used the complexity
leadership theory to explain a leadership paradigm based on enabling the learning,
creative, and adaptive capacity of complex adaptive systems. The key constructs of
complexity leadership theory are: (a) administrative leadership based on strict control and
bureaucratic hierarchy; (b) adaptive leadership based on creative problem solving,
generating new conditions and learning; and (c) action-centered leadership that involves
immediate decision-making mechanisms used in crises and dynamic productivity.
The complexity leadership theory provides a lens through which I explored
effective strategies that managers use to ensure compliance as they pertain to an
increasingly dynamic of instability emanating from regulatory requirements. The
complexity leadership theory is an appropriate framework for this study. Hazy and UhlBien (2015) noted that complexity leadership-inspired research resulted in new insights
into the mechanisms for studying leadership in a dynamic environment by focusing
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leadership efforts on behaviors that help improve organizational performance. According
to Murray (2017), leadership involving interactive model facilitates collaboration across
networks and the performance of a task. Baltaci and Balci (2017) highlighted how
administrators respond to environmental dynamics and relationships necessary for
organizational survival from the perspective of complexity leadership theory.
Operational Definitions
Complex system: A complex system consists of many entities that display a high
level of interactivity (Cordon, 2013).
Compliance: Compliance is an array of behavioral and attitudinal responses of
individuals or corporations to regulations (Mendoza et al., 2016).
Interaction: Interaction is a dynamic mechanism of interdependent behaviors and
relationships leading to the emergence of unrecognizable subsets when perceived as a
linear combination of the initial agents (Proches & Bodhanya, 2015).
Regulations: Regulations are a variety of government rules or authorities that
affect individuals and organizations (Baldwin, Cave, & Lodge, 2012), which
governments institute to strike a balance between the benefits and risks of new products
(Sorenson & Drummond, 2014).
Assumptions, Limitations, and Delimitations
Assumptions
Assumptions in research are statements that researchers hold as factual but are
unproven (Marshall & Rossman, 2016). My first assumption was that each participant
would provide accurate and truthful information. My second assumption was that
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participants would provide accurate descriptions of the strategies used by the company to
ensure compliance with regulatory requirements. My final assumption was that the data
and documents obtained from the organization would be current and help answer the
research question.
Limitations
Limitations refer to potential weaknesses of a study that are out of researcher’s
control (Ritchie, Lewis, Nicholls, & Ormston, 2014). The first limitation of this study
was that I explored only one pharmaceutical organization. The second limitation was the
inability to generalize the findings, given that the study was qualitative. The third
limitation was restricted access to some data due to the need to protect company
intellectual property and maintain confidentiality, which limited the available information
to the researcher. A researcher driving the course of a discussion may influence the
response of participants.
Delimitations
Delimitations are distinctive features resulting from restrictions or boundaries in
the scope of a study and the concerted efforts of the researcher to narrow the scope during
the development of the study plan (Childers, 2014; Marsall & Rossman, 2014). An
important delimitation in this study was the use of purposive sampling to select research
participants. The choice of Nigeria as the geographical location of this study was a
delimitation as well. Another delimitation was the intentional restriction of participants in
the organization to those who were directly involved in management functions and
exercising supervisory role.
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Significance of the Study
The study findings may be of value to businesses because of the understanding it
may offer fundamental strategies that result in regulatory compliance. Given that the
pharmaceutical industry is among the highly regulated industries, managers and
employees in the regulated industry may use the findings to reduce or eliminate the
incidence of noncompliance with regulations. As other scholars have noted, using
efficient strategies results in safer pharmaceutical products and potential for higher
profitability (Page et al., 2015).
Contribution to Business Practice
The associated costs of compliance with government regulations constitute a
critical burden in the pharmaceutical industry, and compliance with government
regulations is critical to the business success of pharmaceutical companies ((Eger &
Mahlich, 2014; Liberti et al., 2016). Responding to regulatory requirements is of
paramount importance to the success of many business organizations (Rollings, 2017).
Researchers show that noncompliance with regulatory requirements impacts companies’
turnover (Nielsen & Parker, 2012). Pharmaceutical company managers may use the
results of this study to develop new strategies required to ensure compliance with
regulations, leading to the emergence of the desired outcome and economic activities.
The findings from this study may provide insights on strategies that may help functional
managers minimize regulatory noncompliance and increase profitability. Functional
managers may gain insights on strategies to minimize regulatory noncompliance and
increase profitability based on the findings of this study.
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Implications for Social Change
Social change results from interdependencies between businesses and the
environment as they interact at various levels (Harper & Leicht, 2015). Social change is
more prominent in successful companies creating socially desirable outcomes such as
generating consumer goods that can contribute to the development of human welfare, as
with the availability of new medications and filling gaps in social provision (Konda,
Starc, & Rodica, 2015; Ney, Beckmann, Gräbnitz, & Mirkovic, 2014). Developing a
strategy to for compliance with regulations enables pharmaceutical organizations to play
key roles in ensuring cost reduction of pharmaceutical products. Reduction in costs
emanates from compliances reducing associated costs with noncompliance. Muzaka
(2013) viewed the availability of pharmaceuticals as a social function that represents
bargaining among government, business, and society. Strategies to improve adaptation to
regulatory changes may lead to the affordability of pharmaceutical products in most
markets, particularly in developing countries given that strategies are crucial to the
supply and availability of pharmaceuticals to the population (Niessen & Khan, 2016).
A Review of the Professional and Academic Literature
The purpose of this study was to explore strategies that managers in
pharmaceutical companies use to ensure compliance with government regulations. In this
literature review, I provide a comprehensive, critical analysis and synthesis of complexity
leadership, rival theories, and a general review of the pharmaceutical regulation. The
literature review consists of three key themes: (a) complexity leadership theory paradigm,
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(b) supporting and rival theories, and (c) the role of regulation in the pharmaceutical
industry.
The literature came from multiple databases, journals, and search engines. In
seeking sources, I used keywords such as complexity theory, compliance, congruency,
Nadler and Tushman, regulation, organizational learning, organization ambidexterity,
pharmaceutical regulation, and drug approval. The search strategy included using
Boolean operator keywords to search databases including Google Scholar, Science
Direct, ProQuest Central, EBSCOhost, ABI/Inform Complete, Emerald Management,
SAGE Premier, and PubMed. I identified additional peer-reviewed publications by
reviewing the bibliographies of articles retrieved from databases. The literature search
resulted in 233 articles, of which 221 articles (95%) were peer reviewed. Of the peerreviewed articles, 187 (85%) had publication dates within 5 years of my anticipated
graduation year of 2018.
Complexity Leadership Theory
Complexity leadership theory (CLT) is an innovative approach to perceiving and
managing complex organizational behavior (Baltaci & Balci, 2017), particularly in an era
of a knowledge economy (Uhl-Bien et al., 2007). Marion and Uhl-Bien (2001) introduced
complexity leadership as an application of complexity theory to the study of
organizational behavior and the practice of leadership. Complexity leadership theory,
according to researchers, is an emerging theory viewed from different angles including
social systems. Research into the theory continued to expand to understand how micro
processes affect follower and leader outcomes (Dinh et al., 2014). Researchers using
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several approaches have conceptualized organizational complexity in relation to size and
technology, design structure, and interdependence among agents within and outside an
organization (Walton, 2014). The interactions of the components in an organization result
in emergent properties and these interactions are nonlinear such that a change in one
component may lead to a large or negligible impact on the whole organization (Gerrits &
Verweij, 2015). While changes in laws and regulations of a project may appear to be the
same for all organizations in a particular industry, the result in each organization might
be different. As such, it is difficult to predict the type of adaptations required by each
organization based on external changes or turbulence experienced by organizations
(Melton, 2017). Complexity leadership scholars view leadership as emanating from
collaboration, complex systems thinking, and innovation mindset to improve cost and
quality (Weberg, 2012).
Complex leadership theory is a framework that scholars use to account for the
development of creative and adaptive strategies and behaviors. The strategies permit
control structures suitable for coordinating organizations and generating results
appropriate to the vision and mission of the system (Uhl-Bien et al., 2007). Scholars of
CLT distinguish between technical and adaptive leadership challenges encountered in an
organization. The resolution of a technical challenge is through the application of specific
technical skill but the solution to adaptive challenges is through emergence based on
interactions of individuals in the organization (Bailey et al., 2012). Uhl-Bien et al.
described the three elements of complex leadership, while Hazy and Uhl-Bien (2015)
further enhanced the complex leadership functions based on Uhl-Bien et al. proposition.
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Uhl-Bien et al. grouped leadership into (a) administrative, (b) adaptive, and (c) enabling
leadership. Proponents of complexity leadership theory explained in broad terms the three
broad types of leadership: (a) administrative leadership, predicated on traditional,
bureaucratic views; (b) leadership that structures and enables conditions; and (c) adaptive
leadership. Hazy and Uhl-Bien (2015) explored complexity study and clarified leadership
influence in the enabling of organizations to perform and adapt. Confronting an
increasing level of uncertainty in business environments, organization leaders have felt
compelled to adapt by mirroring external conditions within the internal environment
(Fitzgerald, Ferlie, McGivern, & Buchanan, 2013; Tong & Arvey, 2015). Uhl-Bien et al.
(2007) itemized four critical assumptions of complexity leadership theory: (a) the
informal dynamic entrenched in context-the nature of interactions and interdependencies
among agents, hierarchical divisions, organizations, and environments; (b) leadership as
an emergent, interactive force leading to adaptive outcomes; (c) adaptive leadership that
occurs in emergent, informal adaptive dynamics in organizations; and (d) adaptive
leadership that requires exploration, new discoveries, and adjustments.
Hazy and Uhl-Bien (2015) surmised that leadership is not confined to an
individual but a form of social and relational organizing among different independent
individuals forming a system of activity. Given the massive regulations imposed on
pharmaceutical companies amid globalization and technological developments,
organizational leaders face complex competitive landscapes driven by regulatory changes
(Duggal, Kashyap, & Kakar, 2014; Palumbo et al., 2015). Organization leaders’
traditional approach to leadership often relied on leaders exercising control to determine
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and direct the future, whereas complex systems leaders facilitate behaviors that enable
organizational effectiveness rather than control (Marion, Christiansen, Klar, Schreiber, &
Erdener, 2016). The theoretical framework of this study has several implications for
leaders in the pharmaceutical industry, as it may create an alternative approach for
leaders to ensure compliance with regulatory requirements. Scholars apply complexity
leadership theory to the study of knowledge-based organizations where knowledge about
a product or service is a major source of competitive advantage to generate unique
contributions to the business (Uhl-Bien et al., 2007). Baltaci and Balci (2017) noted that
leadership in organizations is a significant mechanism capable of managing the
turbulence resulting from changes in technology and innovation.
Other researchers offered a different view of leadership based on a complex
perspective of organizations (Hazy & Uhl-Bien, 2015; Marion et al., 2016). Murphy,
Rhodes, Meek, and Denyer (2017) showed that leaders as enablers disrupt existing
patterns of behavior, promote innovation, and draws conclusion from emerging events.
Given that leaders operate in many contexts, Uhl-Bien et al. (2007) argued for a shift
from the control mechanism perspective to advocating for the development of a
leadership framework in a fast-paced and unstable environment. Baltaci and Balci (2017)
noted that CLT is an alternative approach to study contemporary organizations to thrive
in a volatile, unstable, and chaotic environment. The three primary aspects of complexity
leadership theory based on the identification and exploration of strategies are adaptive
leadership, administrative leadership, and enabling (action-centered) leadership. The
three aspects generate behaviors that promote (a) creativity in organizations, (b) learning,
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and (c) adaptability in organizations when appropriate complex adaptive system
dynamics thrive within a bureaucratic setting.
Complexity leadership theory reflects a significant portion of the core concept of
complexity theory (Marion & Uhl-Bien, 2001). Comprehending complexity leadership
requires an understanding of the fundamentals of complexity theory (Uhl-Bien et al.,
2007). Complexity leadership researchers view leadership as an identifiable behavior of
social and relational organizing between independent heterogeneous individuals
coalescing into a system of action rather than approaching leadership in the context of an
individual (Hazy & Uhl-Bien, 2015; Uhl-Bien et al., 2007). The applications of
complexity concepts to management account for the pattern of social interactions
between independent heterogeneous agents as they aggregate into a system (Hazy & UhlBien, 2015). The complexity approach to leadership is about the relevance of the
overarching organizing effects of individual units, agents, or practices and the impact of
complex systems. Complex adaptive system problems require new learning, innovation,
and new behavioral patterns that fit into the paradigm of leadership development in
which groups learn their way out of a problem. Management development, however, is
the application of established solutions to known problems.
Using complexity leadership theory, scholars can study how interacting
components, whose components are diverse, with a capacity to learn to generate desired
outcomes (Uhl-Bien et al., 2007). Decision-making processes in organizations involve a
cross-functional management approach that comprises planning, discussions, and
resolving issues and implementing decisions for success. Each member of an
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organization brings specialized knowledge about their function to the organization
leading to high functioning teams. In complex systems, given the dictates of complexity
leadership theory, the rules controlling the local interactions change as both internal and
external factors change.
System thinking provides a professional and scholarly alternative approach to
solving and analyzing complicated issues in different fields (Clancy, 2015; Tong &
Arvey, 2015). Walton (2014) provided examples of complex systems across multiple
organizations or systems that included school, healthcare, and manufacturing facilities.
Scholars of systems approach view large organizations such as healthcare organizations
and pharmaceutical entities as complex systems, suggesting that a different strategic
approach is necessary for studying such organizations (Caffrey, Wolfe, & McKevitt,
2016). Hazy (2014) found that human interactions are complex systems with the
leadership performing the functions of organizing a human activity, including unifying
individuals into organized groups and developing a vision, ethics, and identity for the
team. Another function emanating from leadership in complex systems involves changing
rules to spawn ideas and plans of action (Uhl-Bien et al., 2007), allowing for creativity
and problem-solving to thrive in the organization. Lastly, leaders change rules in complex
systems to foster the convergence of divergent individual perspectives and activities into
a viable and expected outcome. Organization leaders must deal with complexities to
avoid adverse impact on their organization’s success (Hazy & Uhl-Bien, 2015).
Researchers from different fields argue that organizations’ paradigms need to
move toward complex systems in which they and their agents can evolve together
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(Caffrey et al., 2016; Clancy, 2015). Certain elements of complex organizations may
themselves be complex, while other elements oscillate between multiple complex
systems (Byrne, 2013). The interaction of components in a complex organization results
in emergent phenomena not explained by evaluating each component in a complex
system (Bone, 2016). A complex systems approach to problem-solving enables
researchers or practitioners to consider wider ramifications consisting of management,
leadership, interventions, and the implementation context of these elements (Caffrey &
Munro, 2017).
Complexity is a critical component of organizations that affects their success
(Hanisch & Wald, 2014). The literature on complexity thinking is diverse, traversing
different disciplines including development, political science, management, biological
science, and physical science. Complexity theory has its roots in physics, mathematics,
and biology, but it has expanded into organizations to inform strategic management and
organizational dynamics. Chandler, Rycroft, Malone, Hawkes, and Noyes (2016)
identified five core concepts of complexity theory: (a) self-organization, (b) interaction,
(c) emergence, (c) system history, and (d) temporality. Revolving around the construct on
complexity are the concepts of chaos, symmetry, entropy, modularity, hierarchy,
nonlinearity, connectivity, equilibrium, synchronization, schemata, self-organization, and
self-regulation (Walton, 2014). The interaction of components in a complex system such
as in pharmaceutical organizations results in an emergent pattern that is difficult to
understand by evaluating individual agents in the organization (Naghshineh et al., 2014).
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Organizational functions and operations are more complex given the increasing
diversification and the number of organizational stakeholders (Baumann & Siggelkow,
2013). Likewise, in heavily regulated environments, many leaders in organizations follow
a management system in which regulatory activities lead to an unpredictable emergent
disturbance that makes it difficult for people to adapt to the change (Battiston et al.,
2016). Using complexity theory has several benefits for understanding complex
organizations operating in highly regulated industries such as healthcare
(Thompson, Fazio, Kustra, Patric, & Stanley, 2016). Complexity theory is an alternative
approach to learn how systems adapt to a disturbance such as regulatory changes through
self-organizing in a way that permits critical system components to endure over a period.
The core of complexity theory rests on the understanding of resilience, which is the
degree to which the system can absorb disturbances as it changes (Bone, 2016). Scholars
use the core concepts of complexity theory as a theoretical framework to evaluate
strategies in healthcare to explain the resistance to change.
The components of complex systems exhibit high levels of interactivity mostly at
the nonlinear level (Poutanen, Siira, & Aula, 2016), with such systems exhibiting fragile
behavior (Clancy, 2015). Fragile organizations are readily susceptible to external
disturbances. Under heavily regulated industries, interactivities result in random events
initiated by an external trigger or disturbance; organization leaders should learn from
other leaders how to lead fragile systems (Cordon, 2013). Nevertheless, some
organizational leaders adapt to changing components and environments through selforganization, learning, and reasoning giving rise to complex adaptive systems
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(Nooteboom & Termeer, 2013; Uhl-Bien et al. 2007). From the perspective of
complexity leadership theory, ability to change and adapt over time through the process
of learning is critical to the success of an organization in a regulated industry (Caffrey et
al., 2016; Mendes et al., 2016).
Scholars, including Bone (2016), employed complexity theory to explain
emergent behavior in previously unexplained changes occurring in different systems. The
results of various studies illustrate the presence of emergence where changes are traced
but difficult to explain by analyzing an individual agent. Looser organizational
constraints promote emergent behavior, and people in learning organizations are more
amenable to complexity as they facilitate adaptive changes (Cordon, 2013). Healthcare
organizations are ideal for the application of complexity theory due partly to the diversity
of organizations and interactions among agents in organizations (Thompson et al., 2016).
Within each healthcare organization, with emphasis on pharmaceutical product
manufacturers, most processes involve interaction between individuals in manufacturing,
marketing, regulatory, professional, and the organizational systems in care delivery.
Complexity theory provides scholars of strategy a framework to explore the
complexities inherent in complex organizations some lessons from the healthcare systems
(Caffrey et al., 2016). Complexity theory has advantages as a theoretical tool in that it
pulls together different viewpoints to develop key concepts and articulates them in a
systematic approach to explain patterns, behaviors, or phenomena in organizational
change and policy implementation (Byrne, 2013; Caffrey et al., 2016). Thompson et al.
(2016) suggested that applying complexity theory to complex systems indicated that
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agents will act, respond, and adapt to changes and environments based on their individual
experiences and viewpoint.
Four elements highlight the interrelatedness of leadership in organizations
through the lens of complexity leadership: (a) network conditions, (b) shared leadership,
(c) organizational learning, and (d) leader skills and knowledge (Clark, 2013). The
implication of Clark and Uhl-Bien et al. (2007) suggestions is that leaders in
pharmaceutical organizations cannot predict complex adaptive systems by a standard
linear equation due to of the interactions between multiple agents of the organization.
Leadership development in complex organizations, including pharmaceutical companies,
emerges from nonlinear and disorderly interactions among the agents (Mendes et al.,
2016). Thomson et al. (2016) opined that adequate functioning of each inter-dependently
connected agent or aggregate depends on the productive state of other actors. The
interactions are strategic because of actions or decisions by one agent influence reactions
by others, which reflect interdependence (Hazy & Uhl-Bien, 2015). I described the three
elements of CLT in the following paragraphs: (a) administrative, (b) adaptive, and (c)
enabling leadership.
Administrative leadership. The management team in an organization is the
administrative leaders where interpersonal influence is predominant (Marion & Uhl-Bien,
2007). Uhl-Bien et al. (2007) noted that a top-down, bureaucratic leadership models in
the last century, thought to be effective in the physical production of goods but not
conducive to a knowledge-based economy. Scholars of the traditional concept view
leadership as a deliberate influence on others to attain the desired goal (Epitropaki, Kark,
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Mainemelis, & Lord, 2017). The contemporary command and control structure of
leadership is ineffective.
Marion and Uhl-Bien (2013) outlined the key organizational outcomes of
administrative leadership are: (a) discipline orientation, (b) consistent routines, (c) role
clarity, (d) clear chain of responsibility, (f) efficiency, and (g) performance. Under this
leadership approach, the leaders establish specific tasks and deliverables while using
discretionary control over resources to bolster successful projects. The leader deploys
resources, e.g., budgets as structural incentives while simultaneously setting challenging
but attainable goals. Marion and Uhl-Bien noted that such leaders provide understandable
roles, targeted training, and follow-up on expected activities while providing resources
and autonomy for the group.
Adaptive leadership. Adaptive leadership is a set of strategies and behaviors
used to facilitate the emergence of solutions from the interactions of individuals in the
organization confronting a challenge (Anderson et al., 2015). The impact of
environmental change results in internal action within the organization that allows for the
possibility to grapple with threats and challenges (Blomme, Kodden, & Beasley-Suffolk,
2015). The changes create the need for managers and other leaders to adapt for the
organization to survive and the strategies deployed by managers to adapt include
communication, active participation, and influence techniques (Bloome et al., 2015). As
managers face external turbulence and complex problems, they require continuous
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adjustment to make the organizations thrive, but many organization leaders cannot cope
with the change required.
One of the core propositions contained in CLT is adaptability, which enhances
performance and innovation that occurs in regular interactions of individuals acting in
response their environments (Uhl-Bien et al., 2007). Adaptability is a fundamental
component of complex leadership theory, helping organization leaders to respond better
to the demands of the environment and formulate strategies favorable to innovations
(Nooteboom & Termeer, 2013). However, certain factors, including employees,
organizational characteristics, and culture, influence decisions within organizations
(Bourke & Roper, 2014). Bourke & Roper (2014) also found significant and consistent
evidence that the impact of knowledge formed by experiential learning has potential
commercial, organizational, and healthcare delivery benefits in a health organization.
The local actions interconnect leading to the emergence of a powerful
phenomenon, but the interconnections are difficult to make because of organizational
bureaucracy and silos (Uhl-Bien & Arena, 2017). Scholars of CLT addressed the central
question of how organizational leaders enable the emergence of solutions to thrive in a
complex and dynamic environment under a bureaucratic setting. The focus is to facilitate
the transfer of ideas across a system by creating a link and brokering. Uhl-Bien and
Arena noted that organizations consist principally of two systems; an operational system
(drives formality, standardization, and business performance) and entrepreneurial system,
which drives innovation, learning, and growth. The conflict emanating from the tension
between the operational system for administrative efficiency and entrepreneurial systems
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striving for learning, creativity, and growth is fundamental to innovation and adaptability
(Mazzei, Ketchen, & Shook, 2017).
Adaptive organizations enable adaptive space by enabling brokerage across
various groups or acting as a catalyst to generate new ideas and promote the development
and sharing of an idea in an entrepreneurial setting. There is an evolution in the
regulation of each industry necessitating efficient strategies to manage relationships
within and outside businesses because of enforcement by regulatory authorities (Riggs et
al., 2016). Despite the abundance of research into leadership studies, researchers paid
little attention to the regulation of businesses at the level of interactions between
individuals in and outside of the business or even among followership (Mendes et al.,
2016). Understanding regulatory dynamics and providing guidance and interpretation
within an organization are fundamental strategic skills that leaders in a regulated industry
must cultivate and continually improve upon (Sravika et al., 2017). Byrne (2013)
suggested that applying complexity theory to regulated organizations enables leaders and
other agents to act, react and adapt based on their worldview, essential for successful
registration and launch of products. The implication is that for any regulation, individual
reactions and the sum of their actions are unpredictable and affect the success of such
organizations (Caffrey et al., 2016). The sum of individual actions affects the trajectory
of an organization; as such, Caffrey et al. noted that daily decisions or reactions to
regulations influence the entire organization. Furthermore, successful people in a
dynamic and regulated environment must develop and implement strategies that
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encourage interactions among agents promote regulatory knowledge and skills of
managers and employees within the organization.
Enabling leadership. The enabling leaders in the CLT paradigm facilitate and
enable the conditions in which an emergent event occurs. The emergent events and
changes are not directly from the leaders but facilitate individuals within organizations
that catalyze and function towards a common goal. Leaders enable the conditions in
which an emergent event occurs, rather than a person and the change are not the direct
from the leaders. Uhl-Bien et al. (2007) found that enabling leadership occurs across
organizations and enabling behaviors more common among middle managers. Galuska
(2014) noted the difficulty in creating the required environment conducive for engaging
the leadership capacity of each individual in the system to optimize performance while
continuing to meet the many administrative, regulatory, and financial requirement within
the organization. The key elements of enabling leadership are: (a) the promotion of
complex adaptive system dynamics that enable conditions that result in adaptive
leadership and emergence, (b) the management of the entanglement of formal, top-down,
administrative functions and informal, emergent, adaptive functions within organizational
settings with different levels of complexity.
Supporting and Rival Theories
The focus in the new leadership development paradigm is the emphasis on social
capital where interpersonal skill development for both the leader and followers is
germane (Haslam et al., 2017). Dinh et al. (2014) revealed that scholars often focused
much of their studies of leadership on individual leadership models geared towards the
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style theories of leadership. Researchers use the organizational learning theory to explore
external influence on organizations is the organizational learning theory. Learning is
critical for organizations to remain adaptive and how organizational leaders and followers
learn is critical in addressing the challenge resulting from external turbulence for an
emergent solution to evolve (Chadwick & Raver, 2015). The increasing level of
turbulence, uncertainty, interdependencies, and interrelatedness is generating some levels
of complexity placing key constraints on traditional or conventional leadership constructs
(Clark, 2013; Uhl-Bien et al., 2007). Most leadership theories relate to individual leaders
exercising interpersonal influence and power to gain commitments and motivation of
others to achieve organizational objectives (Clark, 2013). Organization leaders must
consider all resources and capabilities in their quest to be successful (Waddell & Pio,
2015).
Organizational learning theory. The core of organizational learning is the
collective learning by members of an organization involving the discovery of relevant
new knowledge and dispersing the knowledge to individuals in the organizations to
improve internal processes and external adaptation (Ratnapalan &Uleryk, 2014). Scholars
of complexity leadership theory adduce to the point that in a dynamic system, the need
for leaders to align their strategies, structure, and process with its external environment as
well as relationships are critical (Mthuli, Bodhanya, & Sobratee, 2017). Stettina and Horz
(2015) noted that small groups and teams, such as project teams, committees, and top
management team members perform much of the work in organizations.
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Leaders can influence collective learning by encouraging and nurturing
procedures that increase creative ideas and giving members opportunities to explore new
approaches to performing a task (Chadwick & Raver, 2015). Complexity leadership
scholars stress the importance of learning as a key ingredient of enabling leadership,
which is a major component of complexity leadership theory (Horvat & Filipovic, 2017).
Ratnapalan and Uleryk (2014) argued that in complexity theory, discussions about
systems are difficult to address without focusing on the ability of the agents to learn. To
understand the complex environment, there is the need to promote learning and
organizational learning framework is a key factor for organizational competitiveness and
survival (Chadwick & Raver, 2015).
Over the past few decades, there is a growing acceptance among scholars of
organizational learning as a business strategy (Palos & Stancovici Veres, 2016).
Organizational learning is a mechanism of knowledge acquisition and organizations as
social systems with a culture that promotes or impedes learning. The business aspect
involves attaining competitive advantage through learning, psychological, and behavioral
aspects of individual learning and cross-cultural comparisons of organizational learning
(Mendes et al., 2016). Organization leaders focus on organizational learning to operate
efficiently and maintain a competitive edge through creativity, innovation, and adaptation
to change (Popova-Nowak & Cseh, 2015).
Organizations leaders modify their organizations to acquire new knowledge
through learning practices, creating a supportive learning environment that improves the
learning skills of members who apply knowledge of such learning to modify strategies
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(Onyema, 2014). The release of regulation or guidelines often lead to conditions of
uncertainty (Riggs et al., 2016), and under conditions of uncertainty, team learning is
paramount, contributing to the ability of agents in organizations to improve their
aggregate understanding of a given situation. Team learning helps to accentuate the
relevance of complexity leaders as a catalyst to learning.
Complexity leadership scholars reinforce the importance of learning for
adaptation, enables employees to perform and work towards the mission of the
organization (Naqvi, Khan, & Butt, 2015). Given the challenges that leaders and
followers face because of regulations in the pharmaceutical industry, learning within the
organization offers an opportunity for developing a clear process for sustainability
(Berson, Da'as, & Waldman, 2015). Motivation is a key element that influences
employees learning and knowledge sharing within an organization as noted by Naqvi et
al. (2015). Raina and Roebuck (2016) acknowledged the need for leaders to assign tasks
understandably, communicate effectively, and use multiple channels of communication
when dealing with subordinates. The thinking among organizational learning scholars is
that by creating a culture of organizational learning, organizations can deliver on quality
products and outcomes through continuous improvement from learning (Ratnapalan &
Uleryk, 2014). Organizational learning affects the long-term sustainability of an
organization with a collateral impact on various outcomes (Berson et al., 2015).
Organizational learning theory is a conceptual framework used by scholars to
understand how to improve a company’s performance through individual’s learning,
which in turn affects groups and the entire organization (Santos-Vijande et al., 2012).
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Organizational learning functions through learning mechanism of institutionalized
structural and procedural arrangements, which promote the learning process (Cirella,
Canterino, Guerci, & Shani, 2016). The mechanisms afford organization members the
opportunity to gather, process, disseminate, and utilize data and knowledge relevant to
the organization. The knowledge gained by members stays within the organization
through the dissemination of lessons learned to various groups or units, even with
changes in team members. Organizations perform different activities and functions
designed to promote efficient learning (Seidel, 2015).
Organizational learning involves the creation of new knowledge with influence on
people’s behaviors relative to their work with ultimate impact on the performances
resulting from the creation of new knowledge (Naqvi et al., 2015). Similarly, Ratnapalan
and Uleryk (2014) found that learning has important implications for innovation
processes, competitive advantage, growth, and profitability of the organization. Schilling
and Kluge (2009) identified a series of barriers including behaviors as barriers to
organizational learning that hinder organization members from adapting to the decisionmaking challenges confronting them. Individuals remaining stagnant in an organization
or position over a long period often find it difficult to learn. A key role of organizational
learning is to foster efficiency and effectiveness required for organizations to be
successful (Santos-Vijande et al., 2012). The role of organizational learning is critical
because the learning and knowledge base of an organization results in a competitive
advantage. Furthermore, Ratnapalan and Uleryk noted that organizational learning
provides the setting for integrating the different agents and components into a united
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policy to advance healthcare delivery. Organizational learning provides a framework for
complex, interdependent dynamic systems where each component learns and performs its
activities cooperatively for the production or delivery of desired products (Argote, 2013).
Argote (2013) identified three sub-processes in the study of organizational
learning including creating, retaining, and transferring knowledge. The appropriate
decision strategies or processes need to align with the statutory guidelines that must
include knowledge of clinical, safety, manufacturing, and pharmacovigilance
requirements as enshrined in the guidelines. Company leaders must formulate strategies
on how individuals learn regulatory agencies’ periodic reviews, safety updates, and
adverse event reporting. Sieweke and Zhao (2015) developed a theoretical framework for
analyzing organizational learning, with the core of the framework based on the
interaction of organizational experience and the context leading to the emergence of
knowledge. The introduction of organizational learning has spurred interest among
practitioners and academics as a strategic concept to improve a firm’s success since the
1980s (Waddell & Pio, 2015). Discussions on organizational learning theory emerged in
the 1960s sequel to a change in the thinking among managers that organizations are
organic systems emphasizing relationships between and within groups. The
organizational learning philosophy stemmed from the seminal work of Cangelosi and
Dill, which Argyris and Schon extended and Peter Senge popularized in 1990, gaining
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widespread application in academics and practice (Hu, Found, Williams, & Mason,
2014).
Organization learning theorists lend credence to how organization members learn.
Dasgupta (2011) identified the processes involved and key factors related to the concepts
of organizational learning. The four key variables of how organizations learn include (a)
its experience, (b) copied from others, (c) creation and promotion learning environment,
and (d) what is involved in the development of a conceptual framework. Dasgupta (2011)
further noted that organizational learning has both a weakness and opportunity for
creating new standards in a dynamic business environment. Healthcare administrators
avail themselves of the learning organization concept and promote collaborative learning
among teams as they strive to improve patient safety (Corrigan & Curtis, 2017). Through
organizational learning, companies can increase organizational effectiveness and
efficiency through shared knowledge and understanding.
Researchers also view organizational learning as a system of collective education
with the capacity to transform operations, performance, and outcomes in healthcare
organizations (Ratnapalan & Uleryk, 2014). Teams working in healthcare comprise of
individuals with varied backgrounds working together to deliver the objective of the
organization. Through organizational learning, different inter-professional team learning
and systems-based organizational learning facilitate goals that are vital to managing the
learning requirements in complex, interconnected dynamic systems. Five key aspects of
the concepts and practices are collectivity of individual learning, systems, culture,
knowledge management, and continuous improvement (Ratnapalan & Uleryk, 2014; Tan,

31
2015). Organizational learning is an ongoing phenomenon occurring through formal and
informal learning that leads to organization change (Pallet & Chilvers, 2015; Ratnapalan
& Uleryk, 2014).
Organizational learning theory has inherent flaws. Senge focused on distributed
leadership, which lacks cogent theories, neglects issues of practice and issues of power
(Beauregard, Lemyre, & Barrette, 2015; Caldwell, 2012). Caldwell (2012) argued that
one could conceptualize Senge’s learning organization as a limited mix of systems
thinking and learning theories that result in a perception of organizational learning as a
model of distributed leadership. Managers’ characteristics have high impact on the level
of learning within a firm, but leaders who integrate both technical and administrative
backgrounds promote higher learning among employees (van Hoof, 2014). Van Hoof
recommended a blend of learning method and supply networks as a useful means of
encouraging the implementation of company plans through organizational learning. One
of the key elements of complexity leadership is the flexibility requirements for team
members in organizations to adjust their activities due to changes in internal and external
conditions of the organizations without affecting quality and safety of their products
(Mendes et al., 2016). New regulatory requirements, new knowledge creation, technology
advances, and market changes, for example, add new burdens to pharmaceutical
companies, requiring that they comply with new regulations, organization policies, and
procedures to incorporate new knowledge. Researchers’ understanding of organizational
learning should grow with the continuation of research on current topics, particularly in
areas of knowledge creation and organizational capabilities. Organizational forms and
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technological developments will create both challenges and opportunities for
organizational learning.
In a modern dynamic industry, improving organizational culture is essential given
the frequent changes in the business environment. Organizational culture comprises an
amalgamation of goals, roles, attitudes, assumptions, communication practices, and more
(Belias & Koustelios, 2014). Business organization processes include various activities
and functions with the involvement of many stakeholders (Bauman & Siggelkow, 2013).
The nature of the leadership within an organization defines the culture within it, but
culture is the accumulated outcome of collective learning that begins with leadership
(Shahzad, Luqman, Khan, & Shabbir, 2012). Culture is a combination of shared values,
beliefs, and norms that affect the thinking, views, and behaviors of employees toward
each other and to persons external to the organization (Giorgi, Lockwood, & Glynn,
2015). Organization culture facilitates work attitudes and behaviors to improve the
effectiveness of organizations (Liden, Wayne, Liao, & Meuser, 2014). Similarly, Belias
and Koustelios (2014) noted that attitudes and behaviors in turn, influence the
employees’ approach to the assimilation and manner of response to external factors and
decision-making.
To create a culture of organizational learning, organizations deliver quality
products and outcomes through continuous improvement from learning (Ratnapalan &
Uleryk, 2014). Tang and Yeh (2015) suggested that company culture, current skills,
expertise, organizational structure, the motivation for learning, accommodations for
steady change, and leadership all influence learning. Employees learn about the cardinal
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values of organizations through signs, symbols, stories, ceremonies, organizational
language, and social practices that affect the organization as it cultures matures (Shahzad
et al., 2012). The core of organizational culture is that people are in the organization
because each organization attracts and retains individuals with different personalities,
values, and ethics. The synergy of four essential components defines organizational
culture: (a) characteristics of the people associated with the organization, (b)
organizational ethics, (c) organizational structure, and (d) nature of the employment
relationship (Yukl, 2012). The activities of people in the organization result in
organizations with different cultures, success, and failures (Belias & Koustelios, 2014).
Improving organizational culture is a difficult quest for various organizations and their
people (Yukl, 2012). If employees are committed and share similar value and norms as
their organizations, the organizations achieve their overall goals (Shahzad et al., 2012).
The leaders where the culture of organizational learning thrives have a supportive climate
where employees’ ideas and initiatives blossom (Che-Ha, Mavondo, & Mohd-Said,
2014). Leaders of such organizations also exhibit and foster a culture where members are
tolerant of employee’s errors (Che-Ha et al., 2014).
The global environment, defined by increasing complexity, uncertainty,
nonlinearity, and accelerated change, is increasingly affecting new organizations. The
literature on organizational learning, innovation, and culture traditionally connects these
concepts through linear causality, with the assumption that any one of them is the cause
of another, an approach that is static and contradictory to complexity theory approach
(Chiva, Ghauri, & Alegre, 2014). Leaders in organizations face a high state of
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complexity, and how leaders in those organizations handle these complexities is drawing
the attention of scholars (Albert, Kreutzer, & Lechner, 2015). Leaders require adequate
knowledge of the processes and how to relate with the stakeholders involved in the
operations to make informed decisions about the requirements of activities (Proches &
Bodhanya, 2015). Scholars are showing interest in the interactions among activities
leading to the creation and sustenance of competitive advantage (Albert et al., 2015).
The Congruence Model of Organizational Behavior
Another competing theory I considered for this study as a guide for analyzing the
course of action in this study is the Nadler-Tushman congruence model of organization
developed in the early 1980’s by Nadler and Tushman (1980). Nadler and Tushman using
the congruence model developed a roadmap to analyze organizations as consisting of
interacting components, existing in congruence or fit with one another. Marino, Aversa,
Mesquita, and Anand (2015) suggested that an organization is a system composed of
interdependent parts or building blocks, components, or subsystems operating within an
environment. Nadler and Tushman noted that problems arise in organizations when there
is misalignment or lack of fit among components in the organization. Amis (2018)
posited that in successful organizations, the leaders and followers must be able to respond
to external forces affecting the company by redefining and reorganizing the company to
be in harmony with the environment.
The core competencies of successful organizations are the ability of the people in
the organization to continually adapt to change and master the environment under the
prevailing conditions (Smits & Bowden, 2015). Company executives, managers, and
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employees position their organizations in a flexible state changing the shape of the
organization in response to external influences (Harraf, Wanasika, Tate, & Talbott,
2015). The components of organizations are (a) task, (b) people, (c) structure, and (d)
technology. Nadler and Tushman developed the congruence model for team members to
effectively respond to external disturbances on a company as scholars began shifting their
focus from external planning to internal resources of organization (Seong, Kim, &
Szulanski, 2015).
The goal of Nadler and Tuschman (1980) was to develop a framework more
useful as an analytical tool with emphasis placed on the transformation process and
interdependence of components in organizations. Nadler and Tushman viewed
organizations as consisting of components that interact with each other. The components
attain a state of relative stability, consistency, or fit with each other. The elements of the
company can fit together in a state of harmony leading to the efficient functioning of the
company or loosely fit resulting in problems, dysfunctions, and poor organizational
performance.
The idea of congruence of components is traceable to the work of George
Homans work on the social process in organizations highlighting the importance of
interactions and consistency among critical components of organizational behavior
(Hsiao & Chiou, 2017). Additionally, Nadler and Tushman (1980) drew from the works
of other scholars including, Seiler, Lawrence, Lorsch, and Seldon. Nadler and Tushman
submitted that Lawrence and Lorsch emphasized relationships between differentiation
and integration each organization in response to environmental requirements and the
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relative economic performance. As such, the key components of the Nadler-Tushman
congruence model relate to the questions of: (a) inputs to the organization, (b) outputs the
organization produces, (c) key components of the transformation process, and (d) the
manner of interaction of the components (Nadler & Tushman, 1980).
Toplis and Randell (2014) revealed that managers must understand their
businesses from the four pillars of Nadler and Tushman model and, they must be
sensitive to change, able to reorganize and redefine the company in line with external
forces and demands to make them more efficient. Pharmaceutical companies consist of
different related components, functioning in a state of harmony despite inputs from the
environment to transform inputs into products (Almici, 2015). Using the Nadler-Tushman
model, scholars posit that organizations exhibit key elements of systems theory, which
provided a means of thinking about organizations as complex and dynamic (Seong et al.,
2015). The main characteristics of systems are: (a) internal interdependence, (b) capacity
for feedback, (c) equilibrium, (d) adaptation, and (e) equifinality. Nadler and Tushman
improved on the limit of system theory as a problem solving, which led to their
formulation of a practical model based on the open system paradigm called the
congruence model of organizational behavior.
One of the challenges that managers in regulated industry is adapting the strategy
of their organizations, and they must selectively adapt. Day and Shiemaker (2016)
underscored the importance of selectively adapting and refining organizational
capabilities in periods of rapid change. Amis (2018) noted the importance of leaders
being able to position their companies such that the adaptation strategy does not
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negatively affect their ability to respond to severe changes in the environment.
Organization managers’ may successfully coordinate various resources within the
organization for explorative and exploitative functions that may provide managers with
new opportunities. Under the high regulation, there is little understanding of how leaders
and managers coordinate various actions in response to regulatory requirements
(Pilbeam, Doherty, Davidson, & Denyer, 2016). Leaders and managers in organizations
are responsible for coordinating resource allocation, addressing the routine and changes
emanating from inputs or environment.
The concept of congruence and ambidexterity. According to Nadler and
Tushman (1980), the concept of congruence model is a measure of the fitness of
components in the organization. Congruence theory researchers view organizations
as most effective when the components fit together, and this view in strategy extends to
include the fit between organization and the environment (Wadongo & Abdel-Kadrr,
2014). However, O’Reilly and Tushman (2013) argued that different organizational
forms require different strategies and external inputs. O’Reilly and Tushman (2013)
noted that companies operating in a turbulent environment require a change in structural
alignments requiring managers to strike a balance between exploitation by focusing on
existing viability and exploration for future existence. Tushman and O’Reilly (1996)
posited that organizational managers create ambidextrous organizations to achieve the
desired structural alignments. Junni, Sarala, Taras, and Tarba, (2013) added that
ambidexterity has a positive impact on the success and survival of organizations, based
on the ability to transform and adapt the organizations in the face of uncertainties.
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Ambidexterity as a strategy is relevant in a turbulent environment. In the volatile
and uncertain environment, ambidexterity helps organizations to maintain strategic
flexibility through association existing environment and adaptive to a possible
disturbance. Tushman and O’Reilly (1996) found that the ability of organization
managers to address several activities within the organization concurrently was critical to
the survival of such organization. In highlighting the importance of organizations
operating in a turbulent environment, managers in such organizations need to develop a
coordination mechanism consistent with the key theory of ambidexterity (Heracleous,
Papachroni, Andriopoulos, & Gotsi, 2017).
The regulatory demands imposed on healthcare organizations limit the speed of
product development and market entry of pharmaceuticals and the success of such
organizations (Redden, 2016). The pace of innovation in the pharmaceutical industry and
the response of various regulatory agencies are creating turbulence that is forcing
company managers and leaders to implement strategies leading to the adaptation of their
companies at a faster rate (Redden, 2016). Dunlap, Marion, and Friar (2014) established
that pharmaceutical companies in the face of turbulence and change adapt to through
various forms of adaptation and ambidexterity.
The Pharmaceutical Industry
Pharmaceutical organizations are highly regulated in many markets;
pharmaceutical products require regulatory approval for the development and distribution
(Duggal, Kashyap, Singh, & Kakar, 2014; Liberti et al., 2016). The complex maze of
regulations in the pharmaceutical industry affects every sector of pharmaceutical
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companies, presenting fundamental obstacles to business activities and successful
leadership (Riggs et al., 2016). Pharmaceutical companies belong to an industry where
the core products affect the lives and well-being of the population (Palumbo et al., 2016).
The pharmaceutical industry consists of organizations involved in any of the following
activities: (a) research, (b) development, (c) manufacturing, (d) distribution, and (e)
marketing of pharmaceutical products (Almici, 2015). The spending on these core
products accounts for a significant proportion of the cost of healthcare (Hassali et al.,
2014), accounting for 20% to 60% in developing countries. Almici (2015) articulated the
importance of the pharmaceutical industry to the economy of nations with a particular
focus on the European pharmaceutical sector. The demand for medicinal drugs has forced
stakeholders to demand higher scrutiny of pharmaceutical industry executives by
regulators (Handoo, Arora, Khera, Nandi, & Sahu, 2012). The use of ineffective, low
quality and adulterated pharmaceuticals results in deleterious health conditions to the
public (Amadi & Amadi, 2014). The implications of Amadi and Amadi (2014)
conclusion were the negative outcomes of ineffective pharmaceutical products influence
the confidence of stakeholders in the healthcare system of a country. Individuals from
multiple disciplines are the critical components of pharmaceutical organizations. All
individuals are interdependent with one another within larger interconnected teams. The
interdependence results in the development of safe and quality pharmaceutical products
that satisfy regulatory and other stakeholder demands. The interdependence warrants that
leaders and managers of pharmaceutical organizations need to be flexible to incorporate
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changes in activities, particularly responses to a changing regulatory environment without
compromising product quality (Seidel, 2015).
Nigerian pharmaceutical market. Nigeria is a densely populated country with a
population estimated to reach 207 million by 2020 (Business Monitor International,
2016), indicating an increasing need for pharmaceuticals. The growing population is a
serious challenge to stakeholders on the provision of high quality and cost-effective drugs
(Ogbonna, Ilika, & Nwabueze, 2015). The country also has a high incidence of disease,
poverty, malnutrition, and a growing pharmaceutical industry saddled with the provision
of safe and effective products for this increasing population (Ogaji, Olawode, & Iranloye,
2014). While reviewing capacity utilization in the pharmaceutical industry in Nigeria,
Ogaji et al. (2014) noted the critical impact of the pharmaceutical industry on the
healthcare system of the country particularly concerning essential drug supplies.
Business Monitor International (2016) estimated that the Nigerian pharmaceutical
market in 2016 was worth $905 million and projected value of $941 million by 2020.
Nigerian pharmaceutical companies, contribute 60% of the pharmaceuticals to the
Economic Community of West African States (ECOWAS). However, other ECOWAS
countries such as Ghana are making efforts to increase their participation in
pharmaceutical product manufacture (Akomea, Sorenson, & Amponsah-Efa, 2014).
The Nigerian government has provided infrastructural incentives to the health
sector for the last 20 years in an attempt to solve the problem of drug shortages in the
country. Some of the incentives to promote the pharmaceutical industry were the
establishment of agencies and task forces like the National Agency for Food and Drugs

41
Administration and Control (NAFDAC), Essential Drug List, and National Drug
Formulary Acts (Ogaji et al., 2014). Nigeria’s poor pharmaceutical regulatory
environment is a major hindrance to investment in the sector (Business Monitor
International, 2016). The literature on pharmaceutical regulation in the sub-Saharan
nations is sparse, and how leaders react to regulations affecting the pharmaceutical
industry is still in its infancy. The emphasis in available publications was more on the
politics of pharmaceutical regulation (Olugbenga, 2013). Similarly, other scholars in
pharmaceutical regulations like Amadi and Amadi (2014) focused their studies on the
regulatory agencies approaches to combating adulterated drugs without much discussion
on the implications of regulatory changes on businesses. Nevertheless, Nigerian
pharmaceutical industry leaders continued to operate on a difficult business terrain in an
evolving regulatory landscape (Olugbenga, 2013). Nigerian pharmaceutical companies,
as a reflection of other ECOWAS nations, are under a myriad of burdens directly linked
to product registration issues, particularly in foreign markets (Akomea et al., 2014).
Consequently, regulatory challenges were a critical drawback to sales expansion across
borders in the region, which further explains the importance of regulations as a major
driver of pharmaceutical companies’ successes in Nigeria and other ECOWAS countries,
despite their search for wider markets.
Interdependence in the pharmaceutical chain. The pharmaceutical product
chain is complex, often with different agents and components involved before reaching
the end user of the product, creating both opportunities and challenges to company
leaders (Almici, 2015). According to Almici (2015), the main stages involved in
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providing pharmaceutical products to consumers as articulated are (a) the development
stage, involving the selection of products to develop, the population, and the disease state
to target; (b) registration and marketing authorization required in different markets before
the introduction of pharmaceutical products into markets; (c) the manufacturing process,
involving the production of pharmaceutical products according to set standards and
procedures; and (d) distribution aimed at regular supply and storage of pharmaceutical
product in good conditions to end users and minimizing losses due to spoilage and
expiry.
Interdependencies among agents at various stages of the value chain affect the
strategy and business decisions of pharmaceutical leaders (Caffrey et al., 2016). The
processes or activities involved in the management of a successful pharmaceutical
company leading to a steady supply of products comprised of a complex interrelationship
among the agent and components, both internal and external (healthcare professionals,
employees, regulatory authorities, vendors, and researchers). Managing agents and their
interactions or interconnections in an organization are crucial in a complex organization
(Silva, Silva, & Leite, 2016). The relationship among the agents is relevant for the
emergence of desired outcomes, as leaders must rely on the functioning and efficient
management of relationships to achieve the desired result. Silva et al. (2016) highlighted
the importance of effective management of agents and activities within a healthcare
delivery system. Agents need extensive knowledge and experience accumulated during
professional exercises and through managerial practices to facilitate smooth interactions
(Proches & Bodhanya, 2015).
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Challenges and opportunities often accompany the introduction of pharmaceutical
products into any market and opportunities with a projection of improved healthcare
delivery, reduced costs to consumers, and social change (Brodszky, Baji, Balogh, &
Péntek, 2014). The complexities of the manufacturing process, complexities of
performing clinical work, and adhering to regulatory agencies guidelines are some of the
challenges to overcome (Clancy, 2015). However, in many developing countries, the
healthcare industry is still in its infancy and not well organized as in advanced economies
like the United States, EU, Japan, and Canada. Hence, knowing and complying with
regulations in those regions of the world are challenging to both local and international
pharmaceutical company leaders and other stakeholders (Olugbenga, 2013; Van Norman,
2016).
Pharmaceutical regulatory framework. Regulations are an array of rules that
affect individuals and organizations, which governments use to maintain a balance
between the benefits and risks of new therapeutic products (Sorenson & Drummond,
2014). Pharmaceuticals are among the most heavily regulated products, with many
regulations in place to protect the health and well-being of the population (Handoo et al.,
2012). Because governments at all levels are responsible for protecting their populations,
they will often use regulations as the tool to achieve this responsibility. Regulations are
also tools that governments and their agencies deploy to accomplish the goal of licensing
safe, effective, and high-quality therapeutic products (Balasubramanian, Muthukumaran,
Hariram, Nandhini, & Saisugathri, 2016). The tight weave of regulatory and business
activities necessitates a high-level review of complex decisions critical to the success of
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pharmaceuticals and organizations in highly regulated industries like pharmaceuticals
(Naghshineh et al., 2014). Regulatory authorities also use guidelines to control
Pharmaceuticals at every stage of the pharmaceuticals chain (Balasubramanian et al.,
2016).
Governments establish laws, regulations, and effective national regulatory
authorities to ensure that the manufacture, distribution, and use of pharmaceuticals by
citizens are safe (Maynard & Bloor, 2015; Ogbonna et al. 2015). The rise and rapid rate
of change in regulations implied that leaders in a highly regulated industry like the
pharmaceutical industry would need to remain current on regulatory guidelines to ensure
complete compliance. Business leaders must also understand the impact of regulations on
their business environment to assess potential threats and opportunities in decisionmaking (Riggs et al., 2016), while Anyakora et al. (2017) submitted that regulations
influence the availability, affordability, and quality of pharmaceuticals.
To perform efficient regulatory control, governments often deploy regulatory
tools through specialized agencies to protect consumers in most commercial activities,
including telecommunications, energy, financial, food, tobacco use, healthcare, and the
environment. Examples of government efforts to protect citizens using regulations
include the financial regulations stemming from laws enacted in many countries to
address the cause of the problems in the banking sector following the global financial
crisis of 2007-2009 (Thakor, 2015). Another example was the 2009 Affordable Care Act,
enacted in the United States to increase access to affordable healthcare (Lu, 2014). The
ultimate rationale for regulating commercial activities was to overcome market failures,
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inefficiencies, monopolies, and protect consumers, and these objectives apply to
pharmaceutical regulations (Lu, 2014; Mourlon-Druol, 2016).
The requirements for company leaders to comply with rules stem from (a)
legislative and regulatory agencies (e.g., the Sarbanes-Oxley Act, and Affordable Care
Act 2009), (b) industry standards and codes of practice (e.g., ISO 9000, IEEE), and (c)
business partner contracts. Business leaders continue to struggle to comply with mandates
and timelines required by these mandates. Understanding regulatory dynamics is one of
the key strategies needed for organizational leaders to be successful and efficient in
satisfying stakeholders’ demands while complying with regulatory requirements
(Malerba & Orsenigo, 2015).
The regulations of pharmaceuticals are fraught with challenges, including issues
of manufacture, quality, safety, and tolerability (Mintz, 2015). Regulators use evidencebased approaches to regulations consisting of technology assessment to verify claims
relating to the safety, efficacy, and cost-effectiveness of therapeutic products (Sorenson
& Drummond, 2014) that further constrain company leaders. Many leaders are unsure
how to engage with or relate to regulatory agencies, neither understanding the details in
the regulation of interest nor the benefits of using a particular regulatory process
(Broekhuizen, Groothuis-Oudshoorn, van Til, Hummel, & Ijzerman, 2015). Lack of
understanding may result from the drug regulatory agencies saddled with the
responsibility for regulating drugs, devices, foods, and cosmetics in their countries. The
responsibilities of agencies like the US Food and Drug Administration (FDA) and the
Nigeria National Agency for Food and Drug Administration and Control (NAFDAC) are
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similar to those of several other government agencies, but the resources and demands of
each agency are different (Handoo et al., 2012). Stakeholders, including manufacturers,
distributors, and consumers, find it frustrating and confusing to determine which
regulatory agency and how to engage regulators in obtaining market approval for their
pharmaceutical products (Broekhuizen et al., 2015).
Pharmaceutical regulatory systems. Most countries have established
pharmaceutical legislation and regulatory requirements for the development, and market
approval for the introduction of pharmaceutical products into their countries
(Balasubramanian et al., 2016). While reviewing regulatory guidelines, Balasubramanian
et al. (2016) stated that the level of sophistication in the requirements and depth of items
required for each country varies, depending on the level of their socio-economic
development. The requirements may be in the form of dossier submission for the
complex requirements to a simple notification letter to gain approval (Duggal et al.,
2014). These requirements formed the basis for leaders to have individuals available who
can analyze and understand the commonalities and differences in the requirements of
each country if they are to succeed in this era of globalization (Duggal et al., 2014).
In developed economies like the United States, EU, Japan, and Canada also
classified as regulated markets; regulations are well structured and clear. The rest of the
world such as Brazil (Latin America), Tanzania (Africa), Russia, and others are emerging
markets (Handoo et al., 2012). Regulated markets have defined regulatory requirements
and regulatory agencies that ensure the agencies regulate the manufacture and

47
distribution of pharmaceuticals under strict quality standards to protect consumers in the
entire pharmaceutical products chain (Parvizi & Woods, 2014).
The concerns about the pharmaceutical industry developing medicines without
addressing genuine unmet needs, performing research without due consideration for
research participants, unsubstantiated claims, withholding negative results, adverse
events, abuse of intellectual property laws, and off-label marketing practices has resulted
in high regulation of the industry via a rigorous registration process for drugs (Schramm,
Herbst, & Mattie, 2014). Hence, the ability of medical product manufacturers to
formulate a balanced regulatory strategy is expedient for conducting a fair review of
medical products leading to improved understanding of the medical product development
and approval processes (Bujar, McAuslane, Walker, & Salek, 2017).
In many markets, gaining approval or licensing of pharmaceutical products
depends on the company capabilities gained from the performance of similar
pharmaceutical products (Yousefi, Mehralian, Rasekh, & Yousefi, 2017). Studies on the
decision-making process in the pharmaceutical industry have centered principally on
research and development (Pace, Pearson, & Lipworth, 2015). Decision-making in the
pharmaceutical industry is rife with uncertainty and decisions about what drug to develop
or market and is an important organizational element that requires input from regulatory
persons in the organization (Jekunen, 2014).
The process of regulatory decision-making is the approach that leaders adopt in
regulated organizations involved in pharmaceuticals to conform to regulatory
requirements. The term process relates to the how and is an essential component of a
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company resource that helps eliminate non-essential uncertainties from a plan (Dinh et
al., 2014). The concept of regulation implies a specific array of instructions, deliberate
government interventions, or socioeconomic controls designed to prevent or restrict
unacceptable acts, activities, and processes (Baldwin et al., 2012). Society today is more
industrialized, richer than at any other time, and more regulated from every aspect of
human activity with different theories on the impact of regulation on economics, health,
and social progress of countries in Western Europe and North America (Baldwin et al.,
2012).
Scholars from a host of fields, including law, economics, political science and
public policy, sociology, healthcare, management, and social administration engineered
discussions on regulation (Baldwin et al., 2012). Likewise, scholars and industry
professionals have written on various aspects of regulations including concepts,
challenges, and suggestions, but the literature on leadership in pharmaceutical companies
functioning in a wave of regulations is still evolving. Researchers in the fields of
economics and political science often associate regulation with efficiency, accountability,
transparency, and high productivity, with social welfare implications (Baldwin et al.,
2012). These criteria may lead to wealth creation and are an integral part of economic
theories of regulation classified into two broad groups: (a) public interest theories of
regulation and (b) private interest theories of regulations. On the contrary, Dechezlepretre
and Sato (2017) argued that regulations cause substantial reductions in the growth of
output and effect on labor and capital.
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The reason for the rising interest in pharmaceutical regulation may not be
universal but a result of peculiar needs of the market (Amadi & Amadi, 2014). Amadi
and Amidi (2014) stated that counterfeit drugs as the primary reason for the interest in
national pharmaceutical regulation in developing countries. This contrasts with the highly
regarded regulatory systems in the EU, United States, Canada, and Japan, where the rise
in regulation is the result of new product development and their contribution to healthcare
outcomes (Macdonald et al., 2015). The increase in regulatory activities affects drug
development phases as well as various agents and choices made about regulatory
decisions (Herwig, Garcia-Aponte, Golabgir, & Rathore, 2015). As a result, having
knowledge of a business environment and the impact of regulatory decisions on product
positioning are vital to a product's performance in the market (Mehralian, Nazari,
Akhavan, & Reza, 2014). Likewise, in-depth knowledge of regulations by company
leaders or their designee and their motivation to embrace regulatory changes
companywide saves time and errors in drug approval submissions or licensing
(Naghshineh et al., 2014).
Drug approval process. The FDA, European Medicines Agency (EMA),
National Agency for Food and Drug Administration and Control (NAFDAC) are the
agencies responsible for the evaluation of drugs developed by pharmaceutical companies
for use in the United States, EU, and Nigeria respectively and for granting of marketing
authorization to pharmaceutical companies (NAFDAC, 2016; Naghshineh et al., 2014).
Pharmaceutical products require regulatory clearance before introduction into markets for
the safety of the populace and various government agencies regulate all aspects of the
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product lifecycle (Bedi, Krishan, & Singh, 2017; Warier & Mehta, 2016). Regulations for
market access, manufacturing, and advertising are critical because of the need to protect
the safety and efficacy of products. To highlight the importance attached to
pharmaceutical products, many countries have developed a drug registration system that
involves licensing and inspection of manufacturers and importers of pharmaceuticals for
sale (Balasubramanian et al., 2016).
Regulatory agencies are responsible for the scientific evaluation of medicines for
use in their markets to satisfy the following criteria: (a) efficacy, (b) safety, (c) quality,
and (d) clinical use information (Warier & Mehta, 2016). The licensing or market
authorization process for pharmaceutical products is a critical component of
pharmaceutical laws in most countries. The registration of pharmaceuticals in resourcelimited countries is often to ensure reliable product flow from reputable manufacturers
and distributors (Amadi & Amadi, 2014; Olugbenga, 2013). Warier and Mehta (2016)
found a lack of uniformity in regulatory approval among leading national medical
product regulatory agencies.
Although each country or market has an approval process designed for the needs
and resources of that country, each country’s regulatory process evolved differently in
accordance with requirements and resource availability (Parvizi & Woods, 2014). Each
of the stages of the drug approval process has multifaceted requirements, which sponsors
must fulfill to advance to the next stage in the approval process (Handoo et al., 2012).
The requirements contribute significantly to the high cost of drug development or
marketing in a particular market. Pharmaceutical products already approved in countries
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with developed regulatory systems, as obtained in the United States, EU, Canada, and
Japan often require less documentation to gain market authorization in other countries
(Balasubramanian et al., 2016). A broad overview of the regulatory process for the
approval of pharmaceutical products is provided in Figure 1.
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Figure 1. Overview of the regulatory processes in pharmaceutical licensing.
Many of the drug approval processes in the EU are similar to those of the United
States (Van Norman, 2016) as shown in Figure 2.
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Figure 2. Typical drug approval procedure in the United States.
The evolution of Nigerian pharmaceutical regulations. The National Agency
for Food and Drug Administration and Control (NAFDAC) is the agency charged by the
national government to regulate drugs in Nigeria (Amadi & Amadi, 2014). The National
Agency for Food and Drug Administration and Control Decree Number 15, 1993
established the agency, and functions to regulate food, drugs, cosmetics, and medical
devices. The interest in the formation of a drug regulatory agency in Nigeria began in
1988 following the promulgation of the Counterfeit and Fake Drugs Decree No. 21 of
1988 to combat the growing problem of fake drugs (Ofuani, Kuye, & Ogundele, 2015).
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NAFDAC has nine primary functions as contained in the NAFDAC Act (Food and Drug
Administration and Control, 2016) including:


Conduct appropriate tests and ensure compliance with standard specifications
designated and approved by the Council for the efficient control of the quality of
food, drugs, cosmetics, medical devices, bottled water, chemicals and their raw
materials as well as their production processes in factories and other
establishments.



Undertake appropriate investigations into the production premises and raw
materials for food, drugs, cosmetics, medical devices, bottled water, and
chemicals and establish appropriate quality assurance systems, including
certificates of the production sites and the regulated products.



Undertake inspection of imported food, drugs, cosmetics, medical devices, bottled
water, and chemicals and establish relevant quality assurance systems, including
certification of the production sites and the regulated products.



Compile standard specifications and guidelines for the production, importation,
exportation, sale, and distribution of food, drug, cosmetics, medical devices,
bottled water, and chemicals.
The establishment of various regulatory agencies reinforced the revelation that

Nigerian government has the responsibility to protect the people by ensuring that
pharmaceutical organization leaders and followers to ensure compliance with regulatory
requirements (Ofuani et al., 2015).
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Transition
In Section 1, I introduced the topic, problem statement, and purpose of this study.
The general business problem is that noncompliance with regulation has a negative
impact on company revenue, loss of brand value, product development, product approval,
and regulatory investigations. As such, some pharmaceutical company managers lack
strategies to ensure compliance with regulatory requirements. The conceptual framework
for this study hinges on complexity leadership theory based on the work of Uhl-Bien et
al. 2007. Researcher use complexity leadership theory to understand interactions,
uncertainty, and unpredictability in organizations that arise from multiple interactions.
The literature review component revolved around three themes namely, complexity
leadership theory, (b) support and rival theories, and (c) the pharmaceutical industry.
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Section 2: The Project
In this study, I explored strategies that managers in pharmaceutical companies
use to ensure compliance with regulatory requirements. Using a single case study, I
explored the strategies the managers in the company use to be successful in Nigeria. In
Section 2, I present a detailed approach to the methodology and data collection processes
I followed and the technique to ensure quality in data gathering and analysis. As the
primary researcher, I identify the research method and design to accomplish the purpose
of the study after an in-depth review of scholarly articles and seminal sources. I justify
the selection of research participants, describe my role as the researcher in the study
process, and the selection of the population, sampling technique, and sample size. Lastly,
I discuss the ethical approach to the research study, the data collection and data
organization process, the analysis process, and my approach to ensure reliability, and
validity of the study.
Purpose Statement
The purpose of this qualitative single case study was to explore strategies that
managers in pharmaceutical companies use to ensure compliance with regulatory
requirements. The target population for this study consisted of four pharmaceutical
managers in a Nigerian pharmaceutical company who have successfully implemented
strategies for compliance with the regulatory requirements in Nigeria. The implications
for social change include the potential to improve the abilities of managers to ensure
compliance in a regulated environment, which might lead to increased access,
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availability, and affordability of pharmaceutical products by individuals with limited
access to good healthcare.
Role of the Researcher
The researcher in a qualitative study functions as the primary instrument for
collecting data through interviews, field observations, and document analysis (Yin,
2014). Stake (2013) noted that the researcher is the key driver of the study, whereas
Docherty (2014) posited that the researcher is responsible for selecting and shaping the
theoretical concept of the study. My role as the primary researcher was to design the
study, select research participants, and to provide them with information about the
research process. In addition, I collected and analyzed the data.
Roulston and Shelton (2015) noted that a researcher should be familiar enough
with the study area to understand the central concepts and methodological concerns
relevant to the study. As the primary researcher, I have worked in the pharmaceutical
sector for the past 9 years in various capacities. Presently, I perform regulatory functions
while serving to ensure compliance with various government regulations. My role in
international regulatory affairs is to provide regulatory support within the organization
for the registration and maintenance of the company products and facilities with
appropriate regulatory authorities. As the researcher, my contacts with business leaders
and pharmaceutical industry managers afforded me insight into the nature of those that I
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recruited as participants because of my involvement in international regulatory issues in
the pharmaceutical/medical industry.
The Institutional Review Board (IRB) required researchers to adhere to the IRB
regulations when conducting research (Tsai, 2013). I followed the guidelines of the
Walden University IRB, and the ethical principles and guidelines for the protection of
humans as outlined in the Belmont Report. The three basic ethical principles in the
Belmont Report include respect for persons, beneficence, and justice (Miracle, 2016).
The Belmont Report protocol provides researchers with information to protect the rights
of research subjects or participants (Kawar, Pugh, & Scruth, 2016). In complying with
the principles of the Belmont Report, researchers obtain informed consent, assess risks
and benefits, and select participants. The informed consent process includes disclosing
information about the research study, ensuring participants’ comprehension of the
information, and emphasis on voluntary participation (Miracle, 2016). As the researcher,
I conformed with (a) the ethical principles of the Belmont Report, (b) the guidelines of
Walden University IRB, and (c) the ethical standards of the company. As such, I ensured
that I ethically conducted this research by commencing data gathering only after
receiving IRB approval. I explained the principle of informed consent to participants and
obtained the signed informed consent forms before starting the data collection. In
addition, I safeguarded participants’ identities, provided participants the informed
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consent form, and treated all participants fairly and equally. Lastly, I ensured the highest
ethical standards, including not plagiarizing or falsifying data.
Evers, Hiligsmann, and Adarkwah (2015) noted that bias might occur in a
research study at the planning, data gathering, data analysis, or presentation stage. A
researcher’s understanding of bias is critical because this helps the researcher to evaluate
the literature critically to minimize potential errors in the study. Malone, Nicholl, and
Tracey (2014) advised researchers to minimize systemic bias while trying to eliminate a
specific bias. Researchers introduce member checking in their research design to avoid
bias (Elo, Kaariainen, Kanste, Polkki, Utriainen, & Kyngas (2014). To mitigate research
bias, I designed and adhered to an interview protocol (Appendix A) and used member
checking in the research design. By following the interview, protocol helped me to ensure
that I treated all participants equally, sensitive to contrary views and did not allow my
views to influence those of participants.
Researchers use interview protocols in qualitative studies for data consistency and
reliability (Baskarada, 2014). A good interview protocol enables the interviewer to gain
insight into participants’ lived experiences and learn their opinions (Jacob & Furgerson,
2012). The interview protocol enhances the reliability of a study as it includes an
introduction, purpose, prompts, interview questions, and a blueprint of the case study
report, case study questions, and references (Baskarada, 2014). Researchers using
interview protocol to collect data can conduct their research by speaking with other
individuals, a factor that may lead to a better understanding of the human condition. I
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used the interview protocol to guide me through the interview process and ensured that
all participants received the same information from me as the researcher.
Participants
The choice of participants in a research study affects the success and validity of
that study (Marshall & Rossman, 2016; Yin, 2014). Researchers establish eligibility
criteria in a study to ensure that participants have the requisite insight sought in the study
and indicate their interest to participate (Rengerink et al., 2017). Participants in this study
were managers who have successfully managed or demonstrated effective coordination of
regulatory activities within the selected pharmaceutical company in Nigeria. In this case
study, the participants were members of a leading indigenous, publicly traded
pharmaceutical company with significant supervisory responsibilities for managing
individuals to achieve the who have leadership roles and other responsibilities in the
company value chain, particularly with regulatory responsibilities.
Gaining access to initial contact with participants in qualitative research is
essential to the goal of a study (Keshavarz, Ftahikenari, Rohani, & Bagheri, 2014;
Peticca-Harris & de Gama, 2016). In a qualitative study, a few gatekeepers may be the
principal obstacles to accessing key participants that have relevant information (PeticcaHarris & deGama, 2016). Collaborating with the gatekeepers and having an in-depth
knowledge of the desired populations are ways to overcome the challenges gatekeepers
pose (Anuruang, Davidson, Jackson, & Hickman, 2015). I worked around the gatekeepers
by leveraging my professional relationships and discussing my study with acquaintances
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who have direct access to the senior executives of the company to gain access to the
company.
Researchers need to develop healthy relationships with potential participants to
gain their confidence because interviewing requires building a relationship with the
interviewee (Haahr, Norlyk, & Hall, 2014). Gaining participants’ trust is critical to
building and maintaining a working relationship with the participants and enhancing their
willingness to participate in the research (Andrighetti, Semaka, & Austin, 2017).
Seidman (2012) posited that contacting each participant directly through their
organizations before starting the interview would assist in building the groundwork for
the actual interviews. Bristol and Hicks (2014) noted that providing participants with
informed consent forms helps in gaining participants’ trust. Upon gaining access to the
company, I recruited the participants through targeted direct email correspondence using
the channels provided by the corporate affairs unit. The email contained a description of
the intent of the study and sufficient information to help prospective participants to
decide whether to participate in this study. I assured participants that the interview would
not place them in a vulnerable situation that may jeopardize their positions or harm their
ability to perform their jobs.
Research Method and Design
Three methods are potentially available for conducting research: qualitative,
quantitative, and mixed-method (Yin, 2014). Following Yin’s (2014) work on case study
designs, I determined that the qualitative method was the most appropriate for exploring
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the strategies pharmaceutical company leaders use for compliance with regulatory
requirements.
Research Method
The research method may be any of the following three methods: quantitative,
qualitative, or mixed method (Marshall & Rossman, 2016). I performed a qualitative
single case study for gathering in-depth information from participants to explore the
strategies that managers use to ensure compliance with regulatory requirements. Research
scholars emphasized the importance of a detailed literature search before deciding on the
research method for a study (Baskarada, 2014).
Qualitative researchers study phenomena using open-ended questions that provide
rich and nuanced information based on participants’ experiences, perceptions, and history
in their natural setting (De Massis & Kotlar, 2014). The emphasis of qualitative research
is based on perceptions and experiences taken from only a few participants; hence, the
outcome of the study is not generalizable to an entire population (Grosse, Dixon,
Newmann, & Glock, 2016; Starman, 2013). Because the qualitative method allows for
open-ended interview questions, the research participant is not constrained and is allowed
to capture the often-neglected information (De Massis & Kotlar, 2014). Qualitative
research is subjective, and the key focus is on participants’ perceptions and experiences
relevant to exploratory study (Starman, 2013). The qualitative method will enable me to
collect information on participants in their natural settings and learn about their
individual experiences and interpretations.

62
Qualitative method researchers seek to understand the circumstances associated
with activities, processes, and interactions in shaping and reshaping phenomena (Patton,
Hong, Patel, & Kral, 2017). Researchers employ the qualitative method to explore
underlying reasons that managers choose a particular knowledge set (Yin, 2014). Other
justifications for the choice of qualitative method include a researcher’s ability to explore
various situations and mechanisms in an organization or circumstance. With qualitative
data, researchers can improve the description and explanation of complex concepts in a
clear and concise manner (Bradley, Curry, & Devers, 2007). De Massis and Kotlar
(2014) explained that researchers use qualitative methods for an in-depth understanding
of issues, which is appropriate for exploratory questions Similarly, De Massis and Kotlar
(2014) stated that the qualitative method is suitable for events where the number and
observations available do not readily lend itself to consistent measurement and statistical
analysis.
Researchers use quantitative methods for research that involves statistical data,
measurements, sampling, and analysis of relationships between variables (Bernard,
2013). Quantitative researchers seek to count occurrences, establish a statistical
connection among variables, and generalize findings from a sample to an entire
population (Counsell, Cribbie, & Harlow, 2016). The quantitative method was not
appropriate for this study because the study did not involve the testing of hypothesis or
building of theories.
Mixed method is a methodology for conducting research involving quantitative
and qualitative methods in a single study to collect and analyze data when one a single
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method is insufficient for researchers to understand a phenomenon (Dumbili, 2014). The
mixed method approach requires time and resources for data collection and processing
(Venkatesh, Brown, & Sullivan, 2016). Mixed method was not suitable for this study
because the purpose of this study was not to combine quantitative and qualitative
methods to understand a phenomenon.
Research Design
The research design is a plan that serves as a guide to researchers in the process of
data collection, analysis, and interpretations (Yin, 2014). The study design influences the
conclusions drawn from a study (Proches & Bodhanya, 2015). Qualitative researchers
can choose from a plethora of possibilities that include case study, phenomenology,
ethnography narrative, and grounded theory shared across the social and health sciences
(Yin, 2014). The most appropriate research design for this study was the single case
study. Case study may be a single or multiple case and can be explanatory, descriptive, or
explanatory (Stake, 2013; Yin, 2014). I used a single case study design in this study to
gain a deeper understanding of the phenomena in response to the research question. The
rationale for selecting one pharmaceutical company was to explore the strategies that
managers in the pharmaceutical company use to ensure compliance with regulatory
requirements. The justifications for the choice of single case study included studying a
critical case, an extreme case, a representative or typical case, and, revelatory or
longitudinal case (Yin, 2014).
Case study involves an in-depth data collection from various sources of
information including interviews, observations, documents, field notes, and audiovisual
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materials (Yin, 2014). Case study design affords researchers the opportunity to collect
data in their natural settings through multiple sources of information such as interviews,
observations, documents, and note taking (Morgan, Pullon, Macdonald, McKinlay, &
Gray, 2017). Qualitative research scholars posited that the purpose of a case study is to
provide insightful descriptions of an individual system, phenomenon or situation using
qualitative and quantitative methods for data gathering and analysis (Stake, 2013; Yin,
2014).
Organizations benefit from the rich, holistic descriptions of a phenomenon in its
natural state with the use of a case study design (Hyett, Kenny, & Dickson-Swift, 2014).
Case study has the distinct advantage of generating robustness by advancing the
knowledge and understanding of specific phenomenon while providing in-depth feedback
to research questions (Morse & McEnvoy, 2014). Case study was suitable for this study
to gain an exhaustive understanding of participants’ experiences in organization
processes and business transformation. Yin (2014) made an argument for case study
when the heart of the study hinges on how and why questions.
Two factors are important in a case study: the number of cases in the study and
the number of units of analysis. Stake (2013) noted that the nature of a case study may be
intrinsic (unique), instrumental (improve), and collective (for generalization). The unit of
analysis of the study relates to a phenomenon occurring in a confined framework (Yin,
2014). The case of this study involved compliance with regulatory requirements in a
pharmaceutical company, and the unit of analysis were managers in a pharmaceutical
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company involved directly or remotely in any aspect of the pharmaceutical product's
chain.
Researchers use ethnographic or phenomenological design in qualitative business
research (Yin, 2014). In an ethnographic study, the focus of the researcher is on beliefs,
behavioral pattern, and culture of a group of people (Ferguson, 2016). Ethnographic
researchers conduct their study by observing what participants are doing and saying, or
participate by following participants wherever they go or do their biddings (Ingold,
2014). The sources of data are from sources such as participants’ observation, field notes,
and interviews (Gioia, 2014). Ethnography was not appropriate for this study because my
focus was not on the culture of the people.
In phenomenology, the researcher investigates lived experiences of individuals to
understand the universal and underlying context of a phenomenon (Gill, 2014).
Phenomenology researchers focus on the description of the experiences of participants
and is suited for studies where collected data was from lived experiences of the
participants (Cassel, 2017). I did not select phenomenology for this study given that I did
not seek to explore lived experiences of those going through a phenomenon.
Data saturation in a qualitative study is the point in data analysis where the
collection more data will not result in additional information related to the research
question (O’Reilly & Parker, 2013). Factors including the purpose of the study,
population, research design, method of analysis, and available resources influence sample
size (Hennink, Kaiser, & Merconi, 2017; Malterud, Siersma, & Guassora, 2015).
According to Fusch and Ness (2015), data saturation occurs when no new themes emerge
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from the data gathering. I ensured data saturation at the stage where the data collection
process became counter-productive and until the interview data from participants became
repetitive.
Population and Sampling
The population of this study was functional managers from regulatory, operations,
distribution, and marketing departments from a pharmaceutical company based in
Nigeria. Purposive sampling is suitable for selecting participants given the convenience,
access to participants, and contributions to identifying participants with valuable
information (Lucas, 2014; Palinkas, Horwitz, Green, Wisdom, Duan, & Hoagwood,
2015). Researchers use purposive sampling to explore and to collect a variety of data
based on the experiences of selected participants, with the assumption that participants
will provide a significant amount of information related to the topic (Bernard, 2013; Roy,
Zvonkovic, Goldberg, Sharp, & LaRossa, 2015). I used purposive sampling to select
participants from the population. Bernard (2013) noted that, with purposive sampling,
researchers could recruit participants with an experience that is specifically related to the
study and in a situation where the number of participants was limited. The use of the
purposive method to recruit participants ultimately ensures that a qualitative study results
in the collection of data relevant the topic (Suen, Huang, & Lee, 2014).
Researchers are not unanimous on the sample size for qualitative research, but
most scholars suggest that data saturation is a key determinant of sample size (Hennink et
al., 2016). A small sample size affords the researcher the benefit of analyzing the
complexities of the data by providing better and richer insight into a phenomenon
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(Galvin, 2015). I interviewed 4 participants until I reached saturation and no new themes
or information emerges. Dworkin (2012) noted that 5 to 50 participants in qualitative
research are adequate whereas O'Reilly and Parker (2013) strongly opposed the use of
saturation as a marker of sample size.
Fusch and Ness (2015) stated that failure to reach data saturation in qualitative
research influences the overall research quality and suggested that researchers consider a
research design that is explicit about data saturation. Researchers attain data saturation in
their studies when; ample information is available to repeat their studies, and the ability
to obtain more data and further coding are not achievable or practical (Fusch & Ness,
2015; Morse, 2015). In addition, presenting the same questions to multiple research
participants leads to data saturation (Malterud et al., 2015). I ensured data saturation by
interviewing participants until data became repetitive.
Researchers focus on the selection of participants to ensure that they have those
individuals who can provide accurate information about the topic of study (Bernard,
2013). The participants had the knowledge and expertise on how leaders and managers
ensured compliance with the regulation. Participants provided the interview locations
within the company facility, where they felt most comfortable without distraction during
the interview process. Earp, Mitchell, McCarthy, and Kreuter (2014) noted that the
interview setting is vital to the quality of the research, whereas Yin (2014) emphasized
that researchers should conduct a case study in the natural setting of the case.

68
Ethical Research
An informed consent form is a regulatory requirement for participants to confirm
their willingness to participate in a study after they know all aspects of the study that are
relevant (Rubinstein, Karp, Lockhart, Grady, & Groft, 2014). I obtained Walden
University (IRB) approval with the approval number 11-10-17-0371674 to conduct the
study. Upon Walden University (IRB) approval, I sent an informed consent form to each
participant to review after accepting the invitation (Appendix B) to participate in the
study. Participants who chose to participate in the study signed the consent form and
returned it to me. Participants can withdraw from a study at any time without giving any
reasons (Rubinstein et al., 2014). Participants had the opportunity to withdraw from the
study, by contacting me via phone or email to express their desire to withdraw. I would
have accepted the request and then delete all their information relating to the study.
Participants participated freely in the study without any offer of incentives to
avoid coercion and effect on the quality of the study. As such, I did not offer incentives
for the study. Kennedy and Ouimet (2014) reported mixed outcomes on the use of
incentives to increase participation rate in a study. Researchers need to understand the
ethos of ethical standards and guidelines including avoidance of financial inducement in
research (Polacsek, Boardman, & McCann, 2017). Ethics is an essential component of the
research, that relates to the integrity of the researcher and others associated with the
study. I earned a certificate entitled Protecting Human Research Participants (Appendix
C) to assure that I understood the ethical protection of participants. Pisani et al. (2016)
highlighted measures that researchers use to assure adequate protection of participants
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including (a) adequate informed consent, (b) safeguarding data, and (c) minimizing
intrusiveness and fatigue. I took steps to protect participants through data protection,
maintaining confidentiality, adhering to IRB guidelines, respect for participants, and the
use of informed consent. O'Keefe and Rubin (2015) noted that researchers are bound to
keep the identity and confidentiality of research participants and must de-identify all
information to avoid bias and to obtain an accurate analysis.
I stored all my data in secure cloud storage and on an external hard drive kept in a
secured/locked cabinet only accessible to me for 5 years. Researchers can destroy both
physical and digital data after the 5-year period (Rubin & Rubin, 2012). I identified
participants only by codes (e.g., P1, P2, P3, and P4 for participant 1, 2, 3, and 4
respectively) to maintain confidentiality and use a study number with their documents.
Researchers can identify participants using codes to hide the participant’s identity
(O'Keefe & Rubin, 2015). I redacted all personal information on file, preserved the
confidentiality of proprietary information from key participants in the company, and
upheld ethical codes for researchers to protect participants’ privacy.
Data Collection Instruments
The researcher conducting the interview is the primary data collection instrument
in a case study (Marshall & Rossman, 2016; Roy et al., 2015). As the primary researcher,
I collected, recorded, and transcribed the data collected from the interviews. Case study
researchers may use a variety of instruments for data collection, including questionnaires,
interviews, focus groups, and observations (Baskarada, 2014). Conducting interviews
using teleconference enables researchers to gain access to participants in different

70
locations, provide real-time interactions and opportunity to experience visual cues
(Redlich-Amirav & Higginbottom, 2014). Teleconferencing provides a similar
experience as face-to-face interviews, but good technology and attentive participants
ensure effective meetings (Goodman-Deane, Mieczakowski, Patmore, & Clarkson,
2015). Similarly, Redlich-Amirav and Higginbottom (2014) stated that teleconference is
an appropriate interview setting because it provides simultaneous interaction between the
researcher and participants.
Semi-structured interviews are flexible and afford the researcher a clearer
understanding of the participant’s viewpoints (Wolfe, Gotzsche, & Bero, 2013). Case
study researchers obtain secondary data from multiple sources of evidence (i.e. company
documents, government publications, and routinely collected data) or a combination of
those with the primary data collection instruments (Ketokivi & Choi, 2014; Tijjani,
2014). I used archival records as the secondary data source to the case. The interview
questions were concise so that respondents could easily understand the questions and
respond. The interview form contained open-ended, in-depth interview questions that
allowed for follow-up questions. I conducted interviews in person and via teleconference.
I recorded the interviews digitally. Before data collection, I addressed ethical issues with
participants using the informed consent form to assure each participant of their rights and
confidentiality. I developed an interview protocol based on the framework adapted from
Baskarada (2014) and Wolfe et al. (2013). I began the interview process by contacting the
participants to schedule an appropriate time for a phone interview and sent the consent
form. On the interview date after receiving the completed consent form and confirmation

71
of interview time, I introduced myself, provided a background of the study, reviewed the
consent form, and obtained spoken consent to record the conversations. I informed the
participants of the confidentiality of the interview to reassure them and to make them feel
comfortable enough to offer their opinions and to provide truthful answers to probing
questions. I started with open-ended questions and with follow-up questions as required.
A phone interview process has the advantage of wide geographical access and offers the
opportunity to gain access to research participants who might otherwise be difficult to
reach (Ward, Gott, & Hoare, 2015).
To enhance the reliability and validity of data collection, I conducted transcript
review and employed member checking. Qualitative researchers use member checking
primarily for quality control to improve the accuracy, credibility, and validity of
recordings of an interview (Birth, Scott, & Cavers, 2016; Morse, 2015). I collected
secondary data from available literature including government reports, company reports,
and publicly available data to triangulate the interview data. Multiple lines of evidence in
the form of documentation, field notes, photos, excerpts from multimedia, archival
records, and observations are essential components of a case study (Morgan et al. 2017;
Yin, 2014). I reviewed company websites, publications, government agencies, social
media, and related online resources to gather secondary data. Starman (2013) encouraged
researchers to use multiple sources of data where appropriate to improve the outcome and
validity of their research. Still using member checking, I augmented the data collection
with follow-up questions and checked responses with respondents to ensure the accuracy
of interpretation.
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Data Collection Technique
Researchers are the primary data collection instruments in the qualitative study
and have multiple options for data collection, including interviews, observations,
document reviews, and archives (Morgan et al., 2017). In case study, data collection
involves following case study protocol using multiple sources of data (Yin, 2014). I used
in-person and telephone interview format to collect data, archival documents from the
company, government agencies and industry group. The researcher’s instrument for data
collection is the semistructured interviews, which is a guided conversation and one of the
primary sources of data in the case study (Baskarada, 2014).
A semistructured interview is flexible and allows the researcher to have a better
understanding of the participant (Yin, 2014). Interviews are critical data collection
instruments in a case study, given that interviews are conversations used by researchers to
obtain that information they cannot easily get using other instruments (Baskarada, 2014).
Case study researchers use structured, semistructured, or unstructured interviews. Semistructured interviews are flexible and afford the researcher a clearer understanding of a
participant’s viewpoint (Wolfe, Gotzsche, & Bero, 2013). An advantage of conducting
interviews is the chance for researchers to develop a relationship with participants (Yin,
2014). In addition, Baskarada (2014) noted that researchers use interviews for data
collection to ensure the topic of research remains the focus of the study. I used
semistructured interviews to explore strategies that managers in a pharmaceutical
company used to ensure compliance with regulation.
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Doody and Noonan (2013) and Yin (2014) articulated the advantages and
disadvantages of using semistructured interviews in a study including: (a) participants
may not stray away from the topic, (b) researchers can predefine the interview questions
relative to the conceptual framework of the study, (c) possibility of using interview
protocol allowing for interview confinement to the conceptual framework of the study,
and (d) ability of researchers to explore all the areas required for the research. The key
disadvantage of using semistructured interviews is the difficulty associated with
processing data from it (Yin, 2014). Dasgupta (2015) noted that interviews are slow and
present a concomitant challenge to connect and organize similar statements from
different participants. Another drawback of this technique is that the researchers must ask
questions carefully (Yin, 2014) and appraise what and how to present the questions in the
right context (Baxter & Jack, 2008), which may result in investigator bias (Baskarada,
2014).
In conducting semistructured interviews, six key elements are required: (a)
selecting the type of interview, (b) establishing ethical guidelines, (c) crafting the
interview protocol, (d) conducting and recording the interview, (e) crafting the interview
protocol, and (f) reporting the findings (O’Keeffe et al., 2016). I provided a detailed
description of the data collection technique in Appendix A. Upon receiving IRB
approval, the interview process began by contacting the chosen company contact person
to obtain the contact information of potential participants in the study. After receiving the
list of potential participants, I contacted them via email using the content in Appendix B.
The letter contained a description of the study and an explanation of the requirements and

74
their rights, risks, and benefits. I avoided conflict of interest in all ramification in
participants’ selection process. I stuck to the interview protocol that I designed for this
study to ensure consistency in my approach to each participant.
Researchers may enhance the validity of their study using multiple data sources
including documents, archival records, direct observations, and physical artifacts (Yin,
2014). The key disadvantage of reviewing documents is that they may not accurately
reflect the facts, for example, some of the documents may contain obsolete information
(Baskarada, 2014). However, secondary data are easier to collect, save time and money
(Marshall & Rossman, 2016). The second data source may provide additional
information about the topic not captured through the primary data source. I obtained
additional information from company reports and publications that are publicly available.
Researchers employ member checking to ensure an accurate reflection of
participants’ views (Cope, 2014). With member checking, participants contribute to the
narratives of the findings before the publishing of the study (Noble & Smith, 2015).
Through member checking, I enhanced the confirmability of every aspect of this study. I
regularly checked participant’s understandings of each question and paraphrase and
summarize their responses to each question for clarification. Interview technique requires
the researcher to listen attentively for any new or interesting data the participant provides
(Yin, 2014). Hence, the researcher must have excellent facilitation skills and be an
effective communicator.
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Data Organization Technique
Researchers often organize the data into electronic file systems readily available
and accessible for analysis (Gale, Heath, Cameron, Rashid, & Redwood, 2013). The next
process after data collection is entering the interview transcripts into a storage system
using the right tools (Bernauer, Lichtman, Jacobs, & Robinson, 2013). I took notes and
recorded responses from interview participants using a digital audio recording device
connected to cloud storage for time and cost effective secure data management. Working
with digital systems shortens the time required for transcribing and analyzing data (Yin,
2014).
I organized each participant’s audio-recorded responses, secured the raw data, and
transcribed data in a location mostly accessible by me. I organized the data by keeping
track of signed (a) consent form, (b) invitation emails, (c) transcripts, (d) recordings, (e)
labeling systems, (f) company documentation, and (g) research journals. Yin (2014) and
Stake (2013) acknowledged the relevance of methodically organizing research data. I
stored all the research data in secure cloud storage and on an external hard drive kept in a
secure/locked cabinet accessible only to me for a minimum of 5 years. I transcribed the
interview recordings using MS Word document and then stored them in the same way.
Data Analysis
Triangulation is a critical component to strengthening research validity (Yin,
2013). Qualitative researchers assess and validate their research using triangulation
(Johnson et al., 2017). Triangulation allows for analyzing the research problems from
different perspectives (Johnson et al. 2017; Turner, Cardinal, & Burton, 2017).
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Triangulation involves the use of multiple sources to study a case, minimizing the
weaknesses of research design and enhanced understanding of the case (Turner et al.
2017). Baskarada (2014) identified four types of triangulation: (a) methodological
triangulation, (b) data source triangulation, (c) investigator triangulation, and (d) theory
triangulation. Methodological triangulation involves using more than one method for data
gathering in the study of a phenomenon, which is beneficial in confirming research
findings (Turner et al. 2017). Case study findings are more convincing and likely to be
more accurate with methodological triangulation (Yin, 2014).
I used methodological triangulation to analyze the evidence from multiple data
sources to identify themes that aided in the assessment, interpretation, and deduction
from the information generated. Researchers find themes based on the responses to the
interview questions. I used content analysis to analyze documents obtained from the
study organization for triangulation. The content analysis consists of preparation,
organization, and reporting and counts themes or codes, and can help to identify the most
common topics (Baskarada, 2014). The components of data analysis include three
activities: (a) data reduction, condensing data into themes; (b) data display, which is the
organization of information to allow for deductions; and (c) arriving at conclusions and
verification (Tijjani, 2014).
I used a computer-assisted qualitative data analysis tool called NVivo and
Microsoft Excel to code, identify patterns and themes, and analyze study data. The next
phase was transcribing the recorded interviews and emailing the transcripts to each
participant to confirm that the content of the analysis corresponded to the views
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expressed. Researcher studies the outputs from this software to establish any emerging
patterns, insights, and concepts. I: (a) read in detail each transcription to understand the
contents, (b) read each transcript over again to extract key themes and sentences relevant
to the case study, (c) attributed meaning to each significant affirmation, (d) placed each
meaning into group of themes, (e) supplemented the results with detailed description of
case, (f) described the key structure of the case, and (g) validated the data. Sotiriadou,
Brouwers, and Le (2014) presented guidance for conducting qualitative data analysis
using an NVivo software program and screenshots of the data analysis process. I
analyzed the study data using the framework method for the management and analysis of
qualitative data.
The framework method is a type of thematic analysis or qualitative content
analysis that defines the matrix output: rows (cases), columns (codes), and cells of
abridged data, giving structure to which the researcher can methodically reduce the data
so as to analyze it by case and by code (Ritchie et al., 2014). Researchers using thematic
processes identify similarities and differences in qualitative data before concentrating on
connections between various parts of the data, to arrive at descriptive and explanatory
conclusions clustered around themes (Gale et al., 2013). Framework method is a flexible
tool that a researcher can customize for use with many qualitative approaches with the
objective of generating themes. The procedure for framework method of analysis occurs
in seven stages: (a) transcription, (b) familiarization with the interview, (c) coding, (d)
developing a working analytical framework, (e) applying the analytical framework, (f)
charting data into the framework matrix, and (g) interpreting the data (Gale et al., 2013).

78
Researchers may develop themes using a database, which allows them to develop
audit trails from data gathering, through analysis, and to the final deductions (Baskarada,
2014). The analysis of findings of a study using previous reports or studies and
conceptual framework provide authors with the ideas for articulating themes and
structures (Yin, 2014) for their research. I extracted themes from each unit of analysis
using a conceptual framework selected as the guide theory for this study and information
from published studies. Researchers identify gaps in previous research by extending
existing theory while using a conceptual framework to guide the study (Marshall &
Rossman, 2016).
Reliability and Validity
Evaluating the quality of a study is essential for practical utilization of the results
and drawing useful conclusions (Noble & Smith, 2016), and the quality of any empirical
study including case studies is dependent on construct validity and reliability (Yin, 2013).
What follows is a description of the strategies to enhance the study reliability and
validity.
Reliability
The concept of dependability relates to the accuracy, repeatability, and
dependability of a qualitative study just as ensuring reliability in a quantitative study
(Yin, 2013). Houghton, Casey, Shaw, and Murphy (2013) posited that researchers ensure
dependability and assure high rigor and robustness of the research process and results by
diligently recording the research methodology and decision-making. Researchers may
improve dependability in the study by using member checking (Elo et al., 2014). I

79
allowed participants to check the accuracy of the interpretations of their interview
responses by sharing the data interpretation with the participants to confirm that the
interview data corresponded to the thoughts they expressed. I also ensured dependability
by keeping reflective notes and memos through the interview process and data analysis.
Morse (2015) asserted that member checking enhances dependability by improving the
accuracy, credibility, and validity of data during interviews. Member checking also
allows researchers to improve the quality of their study through validation of transcribed
information with study participants (Birt, Scott, Cavers, Campbell, & Walter, 2016).
Validity
Validity is the extent of compliance with the interpretation of the event and the
realities of the world (Houghton et al., 2013). Also, Houghton et al. (2013) noted that an
account is valid if it accurately portrays the features of a phenomenon that it describes. A
qualitative researcher measures the validity of their research by evaluating the credibility,
transferability, confirmability and data saturation of the study.
Credibility in a qualitative study is the trustworthiness of the findings of the study
(Noble & Smith, 2015). Researchers enhance the credibility of qualitative research
findings through an accurate reflection of participants’ views by using member checking
(Cope, 2014). Likewise, Houghton et al. (2013) suggested that in a qualitative study,
researchers could enhance credibility if participants can verify the descriptions the
researcher presents. Qualitative researchers may assess and validate their studies using
member checking by allowing the participants to review the interview interpretations
(Wilson, Onwuegbuzie, & Manning, 2016). Using member checking, researchers can
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highlight problems by examining data and address any problem to maintain the integrity
of the research findings and strengthen the outcome of the study (Lishner, 2015). I
allowed members to check their interview responses using the interview transcript data to
confirm that the interview data correspond to the thoughts they expressed to enhance the
credibility of the study and to reduce research bias.
Transferability is the extent to which researchers can apply the findings of a study
to similar settings or groups (Cope, 2014). Furthermore, Elo et al. (2014) described
transferability as the potential for readers of the study to transfer the research findings of
the study to another given the detailed description of the critical aspects of the study. Key
components of the research study including research method, description of participants,
and steps taken during analysis (Cronin, 2014; Elo et al., 2014). Researchers use
interview protocols to maintain data consistency (Baskarada, 2014). I ensured
transferability by providing a rich description of the interview process in the interview
protocols and adhering to the scripts in the interview protocols.
Confirmability refers to accuracy, neutrality of study data, and the process of
comparing data collected from multiple sources (Houghton et al., 2013). Morse (2015)
argued that confirmability is the extent to which other researchers corroborate the
outcome of a study to ascertain that the results are true representations of the participants’
responses and devoid of researcher bias. I ensured confirmability by leaving an audit trail
that will readily be retrievable to allow for later inspection by other researchers. This will
allow other researchers to check the pathway of decisions I made in the data analysis. The
audit trail will include the list of questions, actual reports, notes, memos, study protocol,
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transcribed text, bibliography, and related databases. Cronin (2014) suggested that
researchers using multiple data sources overcome bias associated with a single data
source thereby increasing confidence in the result and confirmability of the study.
Data saturation refers to the state where there is enough data to replicate a study
(Fusch & Ness, 2015). Bernard (2013) noted that evidence of data saturation occurs when
the researcher cannot obtain additional information and lack further coding. Malterud et
al. (2015) argued that researchers attain data saturation by asking multiple participants
the same questions in a uniform manner. I interviewed many participants to ensure data
saturation until I reached the point where no new information is emerging from the data.
Transition and Summary
Section 2 includes a discussion of the research methods and design, detailing the
use of a qualitative case study technique. The key elements of this section include my
role as the researcher and the criteria for selecting participants for this study. I identify
the study population and the choice of the purposive sampling method. The section also
contains information about how the researcher ensured high ethical standards and used
in-depth interviews as the data collection instrument. I also explain the method for data
analysis and support statements with relevant scholarly peer-reviewed sources. In
addition, I discuss the approach to mitigate bias while addressing the reliability and
validity of the study. Section 3 includes a presentation of findings and applications of
study findings to professional practice, including an analysis and discussion of the results.
The section will also include the implications for social change, suggestions for action,
and recommendations for further research.
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Section 3: Application to Professional Practice and Implications for Change
In this section, I present the findings gathered from an in-depth exploration of the
strategies used by pharmaceutical company managers to ensure compliance with
government regulations. The findings comprise a description of participants’ responses to
semistructured interviews, document review, emergent themes, and correlation to the
conceptual framework. In addition, Section 3 includes the application to professional
practice, implications for social change, and recommendations for action. I conclude the
study with the recommendation for further research, my reflections on the doctoral study
journey, and conclusion.
Introduction
The purpose of this qualitative single case study was to explore strategies that
managers in a pharmaceutical company use to ensure compliance with regulatory
requirements. The overarching research question of this study was: What strategies do
pharmaceutical company managers use to ensure compliance with regulatory
requirements? I conducted in-depth interviews with four managers involved in regulatory
issues in a company based in Nigeria to gain insight into the strategies managers use to
ensure regulatory compliance. Fusch and Ness (2015) noted that researchers reach data
saturation when no additional information emerges from subsequent interviews. I reached
data saturation after interviewing the fourth participant.
To obtain additional information and to enhance the validity of my study, I
triangulated the interview data with secondary data that I collected from the company,
including: (a) internal corporate documents, (b) annual reports, and (c) company website
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materials. I also reviewed publicly available documents with information about
pharmaceutical regulations and guidelines in Nigeria that included (a) regulatory
agencies’ websites, (b) regulatory guidelines documents, and (c) newsletters to
triangulate the study data. After receiving the IRB approval, before the interview began,
each participant reviewed and signed an informed consent form. I conducted the
interviews at the research establishment and via teleconference with each interview
session lasting between 35 minutes to 45 minutes. Upon the completion of the interviews,
I transcribed the recorded interviews and assigned codes to all participants. Each
participant was assigned a code to protect their identity and maintain the confidentiality
of the participants. The assignment of codes to protect participants aligned with the
observation of O'Keefe and Rubin (2015), that researchers could identify participants
using codes to redact the participant’s identity. I assigned participants numbers from 1
through 4 with P1, P2, P3, and P4 for participants 1 through 4 respectively.
Presentation of the Findings
The overarching research question of this study was: What strategies do
pharmaceutical company managers use to ensure compliance with regulatory
requirements? I used semistructured interviews with eight probing questions and followup questions to allow participants to provide in-depth information about their experiences
in regulatory compliance. I transcribed the interview audio recordings and was careful to
ensure that interview transcripts reflected the contents of the audio recording. De Massis
and Kotlar (2014) noted that researchers enhance the accuracy of interviewee transcripts
by reading transcripts while listening to the interview recordings. After the transcription,
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I followed up with transcript review for participants to validate the accuracy of the
interview responses of their interviews. Some of the participants shared SOPs, employee
training information, regulatory inspection sheet, annual reports, and general guidelines
from authorities.
I used Microsoft Excel and NVivo 11 Pro for Window software to analyze data
and to identify frequent themes and word patterns that participants provided during the
interviews. The data from this study resulted in the emergence of three themes:


Establishment of regulatory affairs unit and engaged leadership enhanced
compliance



Qualified employees and learning enhanced compliance with regulatory
requirements



Strategies to navigate through barriers to enhance regulatory compliance

Theme 1: Establishment of Regulatory Affairs Unit and Engaged Leadership
Enhanced Compliance
The first theme to emerge from data analysis was that the establishment of a
regulatory affairs unit and enabling leadership enhanced compliance with regulatory
requirements in the company. All participants maintained that the establishment of a
regulatory affairs unit in the company facilitated the coordination of regulatory activities.
Each of the participants also emphasized the importance of engaged leadership and how
engaged leaders have undoubtedly influenced the company managers’ compliance with
regulatory requirements. Two subthemes emerged from the main theme: (a) regulatory
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affairs unit, and (b) engaged leadership. All the participants indicated that the two items
contributed to the enhanced functioning of the regulatory affairs department.
Regulatory affairs unit. Analysis of interview data revealed that all participants
(P1, P2, P3, and P4) considered the creation of the regulatory affairs unit as an effective
strategy to enhance regulatory compliance. In particular, establishing the regulatory
affairs unit played a critical role in enhancing managers’ ability to ensure compliance
with regulatory requirements. Because of the establishment of the regulatory affairs unit,
managers and employees were more attuned to compliance with regulations (P1) and
facilitated the building and maintenance of good relationships with various regulatory
agencies (P3). Having a regulatory affairs team responsible for communicating and
implementing regulatory requirements that govern the pharmaceutical industry within the
company has helped to increase employees’ compliance with regulation and minimize
regulators citation. The managers’ position on the establishment of a regulatory affairs
unit strengthened Tanwar, MittalI, Gugnani, and Sharma (2015) assertion that regulatory
affairs unit in the pharmaceuticals industry perform key function given the rise and need
to respond to regulation in a competitive business environment. The regulatory affairs
unit team members work on regulated projects and activities in the company to ensure
compliance with various regulations that affect the pharmaceutical industry.
A key function of the regulatory affairs unit, according to P1 and P3, is the
lobbying of critical stakeholders to ensure total regulatory compliance by the company.
Effective lobbying of stakeholders may secure waivers and shorten the time required for
the regulatory authorities to process documents, grant permits, and approve
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pharmaceutical product distribution (Papaioannou, Watkins, Mugwagwa, & Kale, 2016).
Regulatory affairs unit has a proactive plan on the ways to respond and implement
changes to regulatory guidelines and regulations to ensure compliance with the changes
in legislation (P1). Tanwar et al. (2015) reinforced the importance of having a regulatory
affairs department to provide strategic and operational skills required to address
regulatory requirements for the growth, safety, and effectiveness of pharmaceutical
products to consumers. The unit interprets and disseminates regulatory guidelines across
departments and to vendors, particularly those affected by regulatory guidelines and
updates for their input, adjustments, and lobbying.
All participants (P1, P2, P3, and P4) agreed that one of the ways the regulatory
affairs unit team performed their role was through the gathering of knowledge on
pharmaceutical legislation and a consistent effort to scout for new knowledge on
legislation. Having an adept and knowledgeable individual as the regulatory affairs unit
manager to lead the regulatory compliance efforts of the company is crucial to the overall
regulatory compliance strategy of the company (P3). P2 and P3 substantiated the claim,
noting that, for the unit to function optimally, a qualified pharmacist with experience in
regulatory and quality duties should head the department, liaises directly with regulatory
agencies, and coordinate regulatory activities within and outside of the organization.
Having a knowledgeable manager positively influences the coordination of regulatory
and quality tasks of the company, as well as providing effective supervision of employees
in the unit (P3).
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The team members of the unit maintain proper documentation and records to
provide a picture of the company’s manufacturing, distribution, and marketing operations
as a basis for planning to ensure compliances with regulation (P1). The finding that
adequate record help ensure compliance with regulation aligns with the findings of
Chaudhari, Yadav, Verma, and Singh (2014) who expressed that keeping adequate record
and company documents was critical in compliance. The regulatory affairs team has a
developed a system that allows for an efficient response to regulatory questions from
regulatory agencies and other units of the company.
All participants communicated that the regulatory affairs unit interfaces with
regulatory agencies, and also coordinate their visits to the facilities. The principal
agencies that the regulatory affairs unit interfaces with are (a) the National Agency for
Food, Drug Administration, and Control (NAFDAC), (b) the Pharmacist Council of
Nigeria (PCN), and (c) the Standard Organization of Nigeria (SON) and other statutory
agencies that indirectly impact the operations of the company. Chaudhari (2018)
explained that, in an era where regulatory agencies closely monitor every aspect of
pharmaceutical supply chain and information shared with consumers, the establishment
of a department that liaises with regulatory agencies and coordinate regulatory activities
was critical. P2 and P3 reinforced Chaudhari’s assertion with their inference that the
company seamlessly integrated the regulatory affairs unit into its strategic decisions.
Inefficient interaction with regulatory agencies affects brand, sales, and market shares.
Desai (2016a) posited that organizations establish close collaborative relationships with

88
regulatory agents to overcome uncertainty. Collaborations with regulatory agencies
enhanced organizational compliance with regulatory requirements.
P3 spoke about the involvement of the executive board in the supervision of the
regulatory affairs unit to help resolve complicated regulatory challenges. One of the ways
the unit resolved these challenges was to escalate serious regulatory compliance issues to
the leadership level. The functional head of the regulatory affairs unit escalates problems
through the superintendent pharmacist on the executive board of the company. The
superintending pharmacist reports complex issues that require the input of the
management board members to the executive board. The board is the ultimate decisionmaking body of the company, charged with resolving all business matters not reserved
for the general meeting of shareholders.
Engaged leadership. All participants (P1, P2, P3, and P4) identified engaged
leadership as a significant strategy that enhanced compliance with regulatory
requirements. Specifically, the engagement of the executive board of the company in
regulatory decisions facilitated regulatory compliance. According to P1 and P3, the active
involvement of the senior leadership in regulatory issues was an indication of the
relevance attached to compliance with government regulations and product safety.
Executive board participation and support was consistent with Galuska (2014) who
revealed that producing excellent outcomes requires influence leadership at each level of
a complex system. The board regularly assesses the performance of the regulatory unit
via unrestricted access to information to ensure satisfactory coordination business
activities according to codes and laws by the company.
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All participants believed that three behaviors of the leaders bolstered efforts to
ensure compliance with regulatory requirements. One of the behaviors was the creation
of regulatory vision with concrete goals and objectives, which ensured that managers and
employees understood the significance of regulatory compliance. Second, the participants
in the study also highlighted that fostering strict compliance, by consistently adapting to
regulatory requirements, promoted a conducive business environment. The finding on the
promotion of a conducive business environment echoed the assertion of Chhotray,
Siverstsson, and Tell (2017), that a company vision should mirror a culture that bolsters
employees’ daily activities and decisions. Third, the support of the executive board for
regulatory compliance aided the overall compliance with regulatory requirements in the
company. P3 believed that the leader's engagement with the decision-making on
regulatory activities and resolving issues directly related to regulatory compliance, the
regulatory compliance was obvious companywide. Blomme et al. (2015) noted that
changes create the need for leaders to adapt for the organization to survive and the
strategies deployed by managers to adapt are communication, active participation and
influence techniques. In responding to regulatory developments, the leaders promptly
adapt to changes and the dictates of those involved in regulatory activities.
In summing up the importance of engaged leaders, P1 and P3 mentioned that the
support of the executive board members was important in implementing the requirements
in any specific area affected by any regulation. The focus of the company’s culture
revolved around stakeholders’ interests, sustainability, overall support, and alignment of
company strategic goals, and this influenced the support of leaders for compliance with
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regulatory guidelines and laws. The leaders set in motion strategies that allowed for the
development of key regulatory compliance tools including corrective action and
preventive actions (CAPA), standard operating procedures (SOP), and other internal
compliance documents. Employees used the documents as a guide in their daily tasks as a
way of having a uniform compliance approach to regulatory requirements. P3 stated.
The primary way we assess the measure of noncompliance or (CAPA) is when the
regulatory bodies audit us for assessment, the measure of noncompliance that we
receive is an indication of the effectiveness of our internal systems. We also have
our routine quality audit in our processes that take place from time to time. We
observe how many non-compliances are being reported and whether this
noncompliance is major or minor. Let us not forget that it is also mandatory for
regulatory authorities to always come in from time to time to audit our system.
These two measures give us a feedback.
A review of the document Corporate Governance Practices (D1) obtained from
the company indicated that the executive board was involved in governance and ensuring
that departmental leaders implemented strategies and programs that were supportive of
regulatory compliance. D1 was a corporate governance document that served as an
operating guide for compliance with codes, including best practices and ethical standards
in all aspects of the company’s operations. The document had information on the
governance structure, responsibility of the leadership of the company, and maintaining
amicable relationships with various stakeholders.

91
The information obtained from D1 corroborated the assertion of P1 and P2 about
the involvement of the leaders and facilitating compliance with regulation in the
company. An excerpt from D1 corporate governance document on the role of the
executive board states,
The company continued to subject its operations to routine audit by independent
auditors that include the current Good Manufacturing Practice (cGMP) and the
National Agency for Food and Drugs Administration and Control (NAFDAC). A
committee led by an executive director review the report for appropriate
implementation of the recommendations.
Krause, Semadeni, and Cannella (2013) asserted that board members commonly
influence organizations and accomplish this through any of three primary processes: (a)
offering advice to management, (b) procuring resources for the organization, and (c)
monitoring management having in mind the interests of internal and external
stakeholders. As detailed in D1, the executive management committees drive the daily
affairs of the company headed by an executive director who reports to the board of
directors. The contents of D1 reinforced all participants’ assertion that the executive
board was active in ensuring the accuracy, adequacy and timely rendition of the statutory
returns and reporting to regulatory authorities.
As constituted, the management structure serves to ensure that a standard
procedure for reporting any form of noncompliance by employees or any strategic
business associates is in place to ensure the sanity of their operations and enhance their
reliance on key operational supports. The company leaders considered this important to
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ensure overall sustainability of the company. D1 further revealed that the leaders
predicated their engagement in management and influencing activities on various
government code of corporate governance, compliance requirements, various statutory
rules, and good manufacturing practice. The influencing activities mirror the submission
by Desai (2016b) that the board of directors’ influence activities in an organization.
Correlation to the conceptual framework. The findings of Theme 1 relate to
CLT. CLT was advanced by Uhl-Bien et al. (2007) and the key constructs of complexity
leadership theory are (a) administrative leadership based on strict control and
bureaucratic hierarchy, (b) adaptive leadership based on creative problem solving,
generating new conditions, and learning, and (c) action-centered leadership that involves
immediate decision-making mechanisms used in crises and dynamic productivity.
Specifically, the finding on the establishment of a regulatory affairs unit in enhancing
regulatory compliance relates to adaptive and administrative leadership. All of the
managers noted that the establishment of a regulatory affairs unit facilitated adaptability
to regulatory requirements because the regulatory affairs unit interfaces with regulatory
agencies, and also coordinate regulatory activities within the company. Baltaci and
Balci’s (2017) highlighted the importance of activities coordination in organizations
leading to adaptability to new conditions. The administrative leadership component of
CLT to provides leaders with requisite skills to manage uncertainty rather than overcontrol of every aspect of the business (Waldman & Bowen, 2016). The unit facilitates
the administrative activities of the company including coordination and planning of
regulatory compliance tasks.
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Theme 2: Hiring Qualified Employees, Training and Continuous Learning
Enhanced Compliance with Regulatory Requirements
The second theme that emerged from data analysis was hiring qualified
employees, training, and continuous learning enhanced compliance with regulatory
requirements. All participants (P1, P2, P3, and P4) shared that the hiring of qualified
individuals for the right jobs was critical to the overall regulatory compliance strategy.
The hiring of qualified individuals stemmed from a comprehensive compliance strategy
based on a well-structured hiring and selection program. Training and continuous
learning instituted in the company improved the organization’s compliance with
regulatory requirements (P2). In addition, training created opportunities for employees to
remain current and understand requirement in a dynamic regulatory environment.
Recruiting qualified personnel has an impact on the ability of the workforce to be trained
because regularly trained personnel had a positive impact in maintaining regulatory
compliance in every operation companywide.
Hiring qualified employees. All four participants shared that the hiring of
qualified employees was an essential component of their strategy on compliance with
regulations. P4 explained that to ensure regulatory compliance the company must have
the right people for the tasks. A comprehensive recruitment strategy involved an
established hiring process for all positions in the company. Developing an adequate
recruitment strategy that conformed to the company priorities, skills, and training were
determining factors credited for the company’s prominent level of success with
regulatory compliance. P2 and P4 shared that employees who are lacking an adequate
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background in related jobs, particularly in regulatory issues, undergo basic training on
compliance to understand the pharmaceutical regulatory environment.
The approach to recruiting qualified employees involved generating an accurate
job description touting the skill sets and personality attributes required for completing
tasks and fitting in with the culture of the company. In addition, P2 and P4 indicated that
the company recruitment team uses online recruitment techniques to evaluate key
behavioral traits and the cognitive reasoning ability of the job candidates. The online
recruitment techniques generated information that helped to narrow the field of
candidates to those with a high possibility of fitting into the company’s global
compliance vision. Integrating this online recruitment method has the added advantage
that the contemporary practice of employee screening through online platform influence
recruiting decisions. The finding that online recruitment helped generate information
about applicants that allowed recruiters make better decision aligned with the results of
Melanthiou, Pavlou, and Constantinou’s (2015). Melanthiou et al. (2015) found that a
well-outlined system and strategic application of available information about applicants
significantly aid the recruitment of personnel with the required skills and competencies.
Using different approaches to identify the most suitable candidate for the company has a
critical impact on the ability of the workforce to perform the required task. In discussing
the recruitment of personnel in the company, P3 said,
We have a robust system in place where we strive to recruit people with a
minimum educational background from reputable institutions done through our
human resources department. We do not compromise with the recruitment of
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people with the right qualification to fill openings. We extend our search for the
right candidate by using various mediums to reach out to the right application for
any position in the company.
The highly regulated and knowledge-based pharmaceutical industry requires
qualified personnel to operate in the complicated technical and high-demanding
regulatory environment to be successful (P3). My findings about the recruitment of
qualified employees are similar to those of Mehralian et al. (2014) who found that
intellectual capital and intangible assets are critical tools in for the success of business
entities in a knowledge-driven business environment. Likewise, Oseghale, Mulyata, and
Debrah (2018) found that having intellectual capital was crucial for the success of the
company, especially in the sub-Saharan African regions where a shortage of the right
workforce is rife. P2 believed employees’ experience was a contributing factor to their
successful compliance strategy and the company compensates for the experience by
recruiting individuals with relevant qualifications and then setting them on a training
plan. P4 explained that the company regards human-related challenges as critical, and one
of the ways they overcome the challenge is through the recruitment of qualified
employees who subsequently undergo training and a continuous improvement path. P4
continued the explanation by saying “this is the way we overcome personnel-related
challenges because if you do not have qualified personnel, you cannot trust the employee
to perform their tasks.”
All participants shared that, once recruited for the job, the company used training
as a retaining strategy designed to ensure compliance with regulations. Although turnover
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in organizations is not uncommon, retaining the right applicant is fundamental to avoid
costs and diminished productivity. The company has a recognized human resources
policy designed to create a work environment and that encourages the retention of
employees (P3). Furthermore, P3 shared that the adoption of generous welfare packages,
technical support, and continuous learning in the company led to the retention of
employees. This finding on the adoption of a welfare package to retain employees was
reinforced by Won, Wan, and Gao’s (2017). Won et al. (2017) asserted that employees
who had a comfortable corporate culture, satisfactory emotional and technical support,
work autonomy, and personal development programs were motivated to stay in their
position.
Msisiri and Juma (2017) found that effective employee retention depends on the
continuous improvement of employees, the working environment, employee work-life
balance, and the recognition and appreciation of employees. Haider et al. (2015) stated
that adequate retention strategies were critical to retaining qualified employees. The study
organization considered the retention of employees, particularly the technical staff, as an
important task. Company leaders need to foster conditions that motivate employees to
remain in the organization.
Training and continuous learning. P1, P2, P3, and P4 reported that the
employees training and continuous learning of employees had a positive impact on
compliance with regulatory requirements. All participants observed that company leaders
instituted policies that foster knowledge acquisition by employees. Training was a key
strategy used to ensure regulatory compliance (P3). P3 added that the company policy of
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investing in capacity building and workforce development is to equip and retool
employees in the performance of their jobs. Specifically, the company has an established
training and learning process that enabled employees to gain access to adequate training
and to develop their ability to accomplish desired regulatory requirements. All employees
receive training related to their job function and responsibilities. In addition, employees
receive general compliance training on the company’s compliance program and code as
well as policies and procedures (P2 and P4). Training facilitates employees’ ability to
perform their tasks in accordance with their job description. Training and continuous
learning promote participative culture, interest in knowledge-sharing and internal
capacity development.
According to P1 and P3, the company has a dedicated department charged with
fostering the development of its workforce. Establishing training departments helps the
company to realize its development goal of improving employee knowledge and skills
that are beneficial to the organization. Employees receive training in different areas with
an emphasis on their identified areas of weakness and deficiencies. The company
conducted training in-house and those that needed further training went for external
training both within Nigeria and outside of the country. The company’s focus was to have
employees performing daily operational activities undergo regular training in compliance
with regulatory requirements. These findings align with those of Kroll and Moynihan
(2015) who found that training plays critical roles in closing specific capacity gaps and
facilitates the implementation of new guidelines by providing information about the
guidelines, rationalizing the reasons for the guidelines, and offering employees the
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capacity to operate under new guidelines. Setting up a training department serves as the
coordinating center for the development and growth of employees and the company as a
whole.
P3 shared that,
We have in-house training and external training, both local and overseas,
conferences, seminars, and others. It is a combination of both; there is a training
routine, there is a full-fledged training unit in the organization. We have a
learning and development unit that has the responsibilities to ensure that staff
members are trained in the areas of their weaknesses and the area of their
deficiencies. Both in-house and those that need to go for external training they go
for external training both within Nigeria and outside of Nigeria.
The executive board placed a premium on continuous learning in the company to
keep all employees and third parties attuned to the overall strategic regulatory compliance
goal of the company. Given the importance that company leaders associate with
regulatory compliance, the leaders ensure that employees receive adequate training on
compliance and knowledge acquisition to comply with regulations. The company
regularly reviews the training policy to ensure it meets employee and regulatory
requirements. The leaders’ disposition to adequate training is in agreement with the
findings of Chhotray et al. (2017) who favored a leadership style that encourages the
delegation of responsibility and empowerment of employees in a way that advances
positive outcomes. Reflecting on training, Shin et al. (2017) stated that employees must
develop new skills with the ability to handle new challenges. Because of the frequent
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change in regulatory requirements, conforming to regulatory requirements demands that
company leaders align training and development initiatives with strategic priorities
particularly regulatory requirements.
P3 added that the company policy of investing in capacity building and workforce
development is to equip and retool employees in the performance of their jobs.
Employees receive specialized training, and leaders identify the need for additional
training for those working in regulation-related departments. Specialized training, such as
regulatory learning incorporates an extensive regulatory training curriculum through a
design that combines feedback from training, compliance, and sales representatives. This
strategy reflects Nag and Das’s (2015) inference that an effective approach to training
enhances an individual’s knowledge base. Similarly, Jayakumar and Sulthan (2014)
suggested that effective training programs enhance productivity. P3 mentioned that one
priority for the company was to invest in areas that required the closing of knowledge
gaps through continuous learning. The company achieved continuous learning by
allowing employees to undergo both in-house and external training both locally and
abroad, in the form of conferences, seminars, symposia, and other related training. P2
said,
We train because we believe you need to be well informed as par what you need
to do and also all these are clearly stated in our standard operating procedures
and before you can be placed on the job it is expected that you are trained
properly with relevant SOPs to be sure that even as you do that you are being
monitored, you are being evaluated, and to be sure that you will comply, not even
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only to the various regulatory requirements and some operational details on the
job.
According to P2 and P4, the company employees embark on numerous types of
training to understand regulatory requirements, company policies, and changes to guide
their operational activities. P2 stated that the execution of any change begins with
training on the use of internally developed company documents, such as the Standard
Operating Procedures (SOPs). The SOPs serve as a training document and contains
information about the training of employees on the job and continuous learning in the
organization. The company regularly updates the SOPs to incorporate regulatory changes,
and employees receive training on the SOPs on a quarterly basis to ensure that they
understand current regulatory requirements. Particularly, continuous learning keeps
employees refreshed to minimize the tendency for them to forget useful information (P2
and P4). Employees appreciate the training received regarding the implementation of
regulatory requirements.
The introduction of new products and processes requires that employees receive
adequate training with continuous learning programs about guidelines, required process
training, post market surveillance, and product information (P1, P2, and P4). P2 gave an
example of running a cold chain; employees in the chain undergo concise training in
every aspect of the cold chain process with emphasis on regulatory requirements for
effective control of storage condition, product quality, safety, and performance. While
addressing the effectiveness of training and learning in the company, of P1 said,
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We look at that time compared to what it used to be before, maybe for past 4 or 5
months; I have not had any issue because it shows that the training is working.
Maybe when we start seeing issues coming up. It also let us know people are
losing focus, on this, which also take them back again for training, for us training
is a continuous thing we do.
The company conducts auditing and monitoring activities designed to assess the
effectiveness of training and compliance with regulations by measuring the levels of
variations recorded (P2). An increase in deviations is an indication that employees
involved in the specific area are losing focus suggesting that such employees should
undergo further training, lending credence to the assertion that learning is continuous.
Another way to evaluate the impact of training on compliance was the use of key
performance index (KPI) to assess compliance and to implement actions leading to
minimal or elimination of noncompliance.
For further analysis, enhanced understanding, and increased study validity, I also
used secondary data in addition to the data obtained from interviewing participants. One
secondary data source was an official release on the company’s website (D2) that
described the company’s manpower development strategy. A review of the contents of
D2 indicated that the company has a workforce and learning policy designed to equip
employees with the required competencies and skills to perform effectively and
efficiently on the job. The document revealed that the company training and development
policy has two key objectives namely: (a) to drive a learning culture through strategic
learning interventions that encourage employee growth and development and (b) to
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improve employee productivity and personal effectiveness to achieve a sustainable
competitive advantage. Stated in the D2 is that, “Various programs have been designed to
realize the objectives which include, comprehensive staff orientation/induction program,
internal and external training programs, departmental training, management roundtable
conference, management retreats, seminars and workshops, job rotation, exchange
programs with credible partners, etc.” This excerpt from the company’s webpage
supported all of the participants’ affirmations that robust training and a continuous
learning policy has a positive impact on regulatory compliance.
A high-level overview of the company’s recruitment policy posted on the
company website also provided the roadmap for the recruitment and retention of people
with the right skills and expertise. The website post on the company’s recruitment policy
supported the assertion of P3 and P4 that the company has a robust recruitment process
aimed at hiring the most suitable job candidate. The recruitment policy as posted on the
company website reads,
The company has recognized that an efficient hiring and candidate selection
process contributes to the company’s success with unambiguous effect on the
company’s ability attain its desired goal. The organization attempts to engage and
hire individuals with the requisite skills, expertise, qualifications, and vision to
deliver the company’s our objectives.”
A review of the company 2015 Financial Statement (D3) revealed that the
company has a strong retention incentive. D3 is one of the financial documents that
outlines the financial activities of the company. The incentives serve as part of the
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employee retention strategy of the company and include salaries, pension, and gratuity,
among others. Within this document is the policy statement that “the company incentive
schemes are designed to satisfy each employee needs that include (a) bonus, (b)
promotions, (c) generous healthcare plan, (d) housing and (e) a pension plan in line with
the provisions of the Pension Reform Act 2014.” The document also revealed that the
company attaches high value to training and all categories of employees attend courses
and seminars. These findings from D3 buttressed the assertion by P3 that one of the ways
the company retains employees is by offering a generous welfare package and training.
Good Manufacturing Practice Guidelines for Pharmaceutical Products (D4) is a
document I obtained from NAFDAC that included the guideline on training requirements
in pharmaceutical organizations. Stated in D4 is that “part of quality assurance which
ensures that pharmaceutical products are consistently produced and controlled to the
quality standards appropriate to their intended use and as required by their marketing
authorizations.” The document reinforced the importance that the participants associated
with training to ensure regulatory compliance. The guidance included in the document
ensures the manufacturing of pharmaceutical products that are fit for their intended use,
comply with the requirements of the marketing authorizations and do not place the
populace at risk. D4 compelled manufacturers of pharmaceutical products to maintain
sufficiently qualified personnel to perform all the tasks for which the manufacturer is
responsible.
D4 also has provisions on training requirements for personnel in a pharmaceutical
company including,
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The manufacturer should provide training in accordance with a written
program for all personnel whose duties take them into manufacturing areas or
control laboratories (including the technical, maintenance and cleaning
personnel) and for other personnel as required.



Besides basic training on the theory and practice of GMP, newly recruited
personnel should receive training appropriate to the duties assigned to them.
Continuing training should also be given, and its practical effectiveness
periodically assessed. Approved training programs should be available.
Training records should be kept.



Personnel working in areas where contamination is a hazard (e.g., clean areas
or areas where highly active, toxic, infectious or sensitizing materials are
handled) should be given specific training.



The concept of QA and all the measures, which aid its understanding and
implementation, should be fully discussed during the training sessions.



Visitors or untrained personnel should preferably not be taken into the
production and QC areas. If this is unavoidable, they should be given relevant
information in advance (particularly about personal hygiene) and the
prescribed protective clothing. They should be closely supervised.



Consultants and contract staff should be qualified for the services they
provide. Evidence of this should be included in the training records. Records
should be maintained stating the name, address, and qualifications of any
consultants and the type of service they provide.
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NAFDAC training requirements provided the foundation the company used to
establish written policies and procedures for the hiring of qualified candidates and
training of employees to ensure compliance with applicable laws and regulations. The
policies and procedures apply to all employees and third parties. Adherence to these
procedures is a condition of employment. The company expects all managers to ensure
that their employees and third parties receive training on their specific duties, policies,
and procedures, including all applicable laws, guidance, and regulations.
Correlation to the conceptual framework. Theme 2 aligned with the conceptual
framework of complexity leadership theory. According to complexity leadership theory,
training and learning occur through interactions among agents and their functions (UhlBien et al. 2007). Baltaci and Balci (2017) identified skills, knowledge, and
organizational learning as a critical component of CLT. Baltaci and Balci found that
adaptive responses require learning for improved efficiency in an unstable environment.
Specifically, in the context of this study, training and continuous learning facilitated
employees’ ability to perform their tasks relative to their job descriptions. Company
employees and leaders engaged in training and learning, which increased the level of
regulatory compliance and presented a path for sustainability. Through the learning
strategies used by the company, employees made sense of situations because learning
occurred, and the knowledge created allowed the employees to adapt to regulatory
requirements. Hence, training and continuous learning increased the company’s
regulatory compliance through shared knowledge and understanding.
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Theme 3: Strategies to Navigate through Barriers to Enhance Regulatory
Compliance
The third theme to emerge from data analysis was that having strategies to
navigate through barriers to enhance regulatory compliance. All participants (P1, P2, P3,
and P4) shared that barriers including (a) government barriers and (b) critical factors
comprising finance, technical, infrastructure, and culture influenced managers to ensure
compliance with regulatory requirements. Government barriers and critical factors
influenced efforts to ensure compliance with regulatory requirements because of the
burden that they placed on the company. Navigating through the barriers required
strategies designed to help overcome each hurdle in the highly regulated pharmaceutical
terrain. Overcoming these barriers required the company to adjust to regulatory and
market realities while adapting to emerging issues for sustainable performance despite
the barriers.
Government barriers. An analysis of interview data suggested that overcoming
government barriers had a critical impact on regulatory compliance (P1, P2, P3, and P4).
According to P2, the company encountered obstacles in their quest to fulfill regulatory
obligations. Frequent changes in government policies and a multiplicity of guidelines,
codes, and laws were obstacles identified by P1, P2, and P3 as critical to the company’s
ability to comply with regulations. The challenges the company encountered with
government obstacles induced the leaders and managers to approach regulatory
compliance in innovative ways by formulating strategies that were beneficial enough to
outweigh the costs of those regulations for the company. Overcoming some of the
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barriers require formulating a comprehensive approach that included the direct
involvement of company leaders and representatives of the regulatory agencies.
Regulatory officers’ own experience and biases affected conclusions on
regulatory issues (P3). Dialogs with the assigned regulatory officer for a particular
regulatory compliance project helped clear areas of concern to satisfy regulatory
requirements. P1 cited an example where, upon the submission of an application to
NAFDAC, officials of the agency insisted on facility inspection, despite having a valid
GMP certificate valid for 2 years, in addition, the routine inspection conducted
biannually. The double inspections led to complicated arrangements that greatly affected
production as well as financial performance of the product because of delayed
introduction of the product lines. P3 particularly expressed the displeasure of the
company because of the complicated arrangements affect that overall business output of
the company. Repeated inspection had an extensive impact on business operation and
other activities in the facility because inspectors were not particularly concerned about
the implication of timelines when they planned their site visits. P4 stated,
Making an effort to comply with regulations sometimes helps but some
government officials deliberately make things difficult. The regulatory agencies
may disagree with what the company provided leading to delays and collateral
impact on other activities about the manufacturing and other business operations.
The company addressed such challenges through persistent dialogs with the
regulatory officers assigned to the company.
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With the experience of the company on regulatory matters, P1, P2, and P4
asserted that the company always conducted a diligent review of (a) sample, (b)
submission timeline, and (c) “compliance directives” issues, to prevent questions and
deficiencies before approaching regulators for product registration, annual renewals, or
facility inspection. Lack of adequate preparations, revisions of documents, and effective
planning often resulted in delays of other activities because of logistical issues and
potentially repeating the entire process. Adequate preparation before indicating to the
authorities that the company had a product requiring registration was a key determinant
of the successes achieved in regulatory compliance.
All participants (P1, P2, P3, and P4) explained that multiplicity and duplication of
government agencies roles and lack of definitive differences in the functions of some
regulatory agencies was an obstacle to regulatory compliance. Participants’ assertion
about the duplication of functions by government agencies and the general public-sector
inefficiency buttressed Adanri’s (2016) observation that that public-sector incompetence
was a contributory hindrance to business operations in Nigeria. P4 stated,
Talking of government, the challenge is mainly related to the bureaucracy. One
must move from one office to the other to have files processed, but recently we
have noticed some changes because one of the agencies has introduced online
submission of applications to overcome the burden of physically moving files
from one table and office to another. This challenge with bureaucratic obstacle
also involved having us traveling hours away from our location the main offices
of the agencies. On reaching these government offices, we ended up waiting in
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the office for hours certain activities that could be executed online. However, after
persistent dialogs with regulators, we observed that some of the regulatory
impediments were addressed by the regulatory authorities’ resulting in a lower
rate of delays from regulatory authorities. As a result, many companies are
complying, and particularly, companies like us that are always interested in
compliance in every area of our processes both quality control, engineering,
production, and documentation.
P1 and P4 attributed the proactive approach to regulatory issues that involve
frequent interactions with key government agencies with direct impact on product
imports, manufacturing, and distribution helped managers and employees to meet the
expectations of each regulatory agency. The regulatory affairs unit respond to the issue of
duplication by customizing their responses to each agency to meet their specific needs in
the format required by the agency. The regulatory affairs unit liaises with each regulatory
agency by identifying what the regulations are, which is foremost especially when
dealing with the respective agencies (P2). Understanding the role of each regulatory
agency in the pharmaceutical product value chain is essential to ensure that every product
destined for distribution undergoes the required regulatory approval from product
development through final consumption. The company maintained a checklist and
additional follow up on the checklist generated for each regulatory agency with direct
impact on the company business operations. Employing a system that leads to improving
the compliance, built on a mutual working relationship between the organization and the

110
regulatory agencies, and helped mitigate the negative impact of the uncertainties in
regulatory policies.
Critical factors. P1, P2, P3, and P4 all expressed that critical factors influenced
compliance with regulatory requirements. All participants indicated that critical factors
included (a) culture of the people and their way of life, (b) finance, (c) infrastructural
development, and (d) availability of resources. P2 and P3 particularly noted that business
operations in Africa were challenging given the hurdles pharmaceuticals companies must
contend with. P3 stressed that the cost of complying with standards was high because
guidelines required that a number tests be conducted but the costs and availability of the
materials made compliance almost impossible. P3 said, “The way that we conduct
businesses in the African environment, where we do not have the types of resources
available to companies in the West made regulatory compliance almost
impossible.” Financial constraints on procuring equipment and materials increased the
cost of compliance for products with the required quality standard, making these products
expensive by Africa standards. Access to critical materials required for production is
significant because local companies import most of the materials used in production
thereby creating difficulty in product manufacturing chain.
In addition, P1, P2, and P3 identified cultural constraints resulting from the
mindset and attitude of the people. The people do not necessarily consider adherence to
standards and compliance with regulations, guidelines, and code a priority. Using various
campaigns to explain the importance of quality products that result from regulatory
compliance influenced the noncompliance mindset of the people. Cultural influence
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reinforced Bourke and Roper’s (2014) assertion that critical factors, including employees,
organizational characteristics, and culture, influence decisions within an organization.
Influencing the mindset of the general populace has an impact on overall compliance
with regulatory requirements.
All participants considered critical factors as extraneous barriers that company
must work around by formulating strategies to enhance compliance with regulation.
According to P3,
If you have an infrastructural deficit, which is beyond your control, the company
must provide alternatives. For instance, where you do not have electricity, you
provide your generator, where you do not have low-interest rates loans; you must
find other ways of bringing either equity for your business or raise debt.
The company worked with business advocacy groups such as the Manufacturer
Association of Nigeria (MAN) and the Pharmaceutical Manufacturer Association of
Nigeria (PMAN). These advocacy groups engaged with the government and regulatory
agencies in discussions to work on the constraints identified by business operators. The
advocacy groups also mounted pressure on the government and society by organizing
public discussions, press conferences, and press releases. Individual companies cannot
assert the kind of influences that the advocacy groups bring to bear. The advocacy groups
attempt to collaborate with similar organizations to shape or influence, agencies
responsible for creating and enforcing mandates and to advocate for the provision of a
conducive business environment.
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NAFDAC and PCN (D5 and D6) are documents I obtained from statutory
agencies that detailed the statutory responsibilities of the regulatory agencies indicating
that different regulatory agencies have varied requirements. A review of D5 and D6
revealed that each organization has a specific regulatory oversight function in the
manufacture, distribution, and practice of pharmaceuticals in Nigeria. Regulatory
agencies developed various guidelines for the registration and distribution of
pharmaceutical products in Nigeria. D5 indicated that NAFDAC is the agency mandated
to regulate and control the importation, exportation, manufacture, advertisement,
distribution, sale, and use of pharmaceutical products in Nigeria. NAFDAC performs its
functions by issuing guidelines on the requirements for registration of pharmaceutical
products, including distribution, marketing, and storage of the products for safety and
efficacy.
D6 indicated that PCN functions in the issuance of establishment licenses to
companies involved in the importation, manufacturing, and retail pharmacy. In addition,
PCN is responsible for granting licenses for practicing pharmacy in the country. The
pharmacist for each facility, company, pharmacy, or establishment must be the
superintendent pharmacist who oversees the pharmaceutical organization. PCN grants
license for establishments or pharmacists who will run or oversee the pharmaceutical
processes that occur in that establishment and ensure that they are accountable for these
pharmaceutical processes.
Correlation to the conceptual framework. Theme 3 aligns with complexity
leadership theory. In CLT, leadership is attained through the interaction of three
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functions: (a) administrative, (b) adaptive, and (c) enabling Mendes et al. (2016). As it
relates to this study, administrative function entails managerial activities of the company
including coordination and planning of tasks. To navigate through barriers to ensure
regulatory compliance, the company engaged in the formal planning of tasks such as a
diligent review of (a) sample, (b) submission timeline, and (c) compliance directives
issues. This allowed the company to prevent deficiencies before approaching regulators.
The adaptive component of CLT related to this study emerged from complex interactions
between the company, regulators, and other stakeholders with regard to conflicts, ideas,
and preferences. Navigating through barriers requires adaptability in response to
challenges and opportunities that enhance performance and innovation (Arena & Marion,
2016). The interactions between agents, including government agencies, advocacy
groups, and the company lead to adaptive change. In this study, the company, regulators,
and advocacy groups engaged in interactive exchanges to solve challenges that they
faced, which is an adaptive function.
Applications to Professional Practice
I conducted a qualitative single case study to explore the strategies used by
pharmaceutical company managers to ensure compliance with regulatory requirements.
Data obtained from interviews with four functional managers and company and public
documents provided insight into the organization’s compliance with regulation in the
pharmaceutical industry. Companies who comply with regulatory requirements have a
higher chance of being successful (Rolling, 2017). Using strategies that encourage
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regulatory compliance can eliminate or reduce unnecessary enforcement and compliance
costs associated with legal actions between companies and regulatory agencies.
Noncompliance with guidelines, codes, standards, and laws significantly affects
organizations’ image and profitability (Mulinari, 2016). The findings in this study might
provide managers and organization leaders with information relevant to the running of
pharmaceutical businesses in a highly regulated business environment. Understanding
what strategies led one organization to successful regulatory compliance could allow
other organizations to identify and mitigate issues that may lead to noncompliance of
their organizations as well. When organizations imperfectly comply with regulations,
company operational costs increase because of the cost implications of fines and
corrective actions.
Another contribution to professional practice relates to the influence of senior
leadership in ensuring compliance with regulatory requirements. This study findings
revealed that leaders’ involvement and engagement in compliance strategies helped
facilitate a compliance culture in the company. Increased engagement among senior
leaders in ensuring regulatory compliance can lead to a solid reputation with regulators
and customers, ultimately affecting company revenue and overall business performance.
Implications for Social Change
This study has implications for social change. The pharmaceutical companies play
a significant role in driving social change in the community. The core of pharmaceutical
business outputs is designed to improve and save people’s lives, which is consistent with
the position of Konda et al. (2015) and Ney et al. (2015) that social change includes
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generating good deeds critical to human welfare development and availability of
pharmaceutical products. The availability of pharmaceutical products as a contribution to
social change reinforces Muzaka’s (2013) position that the availability of pharmaceutical
products was a social function that represents bargaining among government, business,
and society. Availability of pharmaceutical products has implication on the overall health
of communities. Compliance with regulatory requirements ensures that pharmaceutical
companies develop high quality and safe products, which are critical in healthcare
leading to the prevention, alleviation, and cure of diseases. Lack of access to quality
medicine remains a vital issue in many communities, hence having strategies that lead to
the development of pharmaceutical products through regulatory compliance will help
combat drug shortage.
Effective compliance regulatory strategies yield considerable social benefits,
particularly in cost reduction. The inability of organizations to comply with regulatory
requirements can be costly resulting in costs that companies transmit into the overall cost
of the pharmaceutical products. Anyakora et al. (2017) noted that regulatory compliance
can influence the availability, affordability, and plays an important role in cost reduction
of pharmaceutical products. Niessen and Khan (2016) noted that having strategies to
improve regulatory compliance might result in the pharmaceutical products that are
affordable in most markets. Disruption of products supply may lead to societal ills, death,
and public health hazard.
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Recommendations for Action
Pharmaceutical companies in Nigeria and sub-Saharan region of Africa can use
the information in this study to develop strategies to ensure compliance with regulatory
requirements. The findings signaled that pharmaceutical company managers might
improve the level of regulatory compliance as a way to avoid the negative impact of
noncompliance such as fines, company image, and reduced profitability. The strategies
shared in this study might contribute to the success of company leaders and managers
who lack the knowledge and strategies to ensure regulatory compliance. An increase in
the level of regulatory compliance might result in increased productivity, profitability,
and company success.
The first recommendation is for pharmaceutical companies to establish a
regulatory affairs unit with responsibility for handling all regulatory and compliance
issues in the pharmaceutical product value chain. The regulatory affairs unit will serve as
the coordinating center for the implementation of regulatory requirements. Tanwar et al.
(2015) conducted a study on regulatory affairs unit in pharmaceutical companies and
found that the regulatory affairs unit provided the strategic and operational skills required
to address regulatory requirements effectively. Second, implementing a comprehensive
recruitment strategy, which leads to the recruitment of only qualified employees to
perform specific tasks. Mehralian et al. (2014) found that intellectual capital was critical
to the success of the business organization. Third, I recommend that pharmaceutical
company functional managers and leaders review the findings of this study on training
and continuous learning because implementing a strategy that fosters knowledge acquired
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through training and continuous learning facilitates employees’ ability to perform their
tasks. Lastly, company leaders should formulate a comprehensive strategy that includes
senior leadership member’s direct involvement with representatives of regulatory
agencies.
Researchers have many ways to disseminate their research findings including, (a)
by presenting the findings as a policy brief to a non-specialized audience, (b) publication
in a peer-reviewed journal, signaling the acceptance of the research within the
community, and (c) writing a book from based on the research findings. I will
disseminate the result of this study via scholarly journals, training, conference
presentations, and developing the study into a book. I will provide a summary of the
findings to the research establishment and specialized trade groups involved in both the
pharmaceutical industry and in general regulatory compliance. I hope to disseminate my
findings widely.
Recommendations for Further Research
This study was an exploratory study to understand the strategies used by
managers to ensure regulatory compliance using complexity leadership theory as a
theoretical guide. In this qualitative case study, I explored strategies used for compliance
with regulatory requirements. In evaluating findings from the research, it is pertinent to
note the limitations and context of this study while suggesting areas for future research.
The first recommendation for further research is to extend the study to multiple
pharmaceutical companies in the country to obtain results with wider reach given that this
study was limited geographically to Nigeria and one organization. Yin (2014) noted that
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with multiple cases, researchers have the possibility of direct replication, or might offer
contrasting situations. In addition, the study was limited to functional managers, thereby
limiting the number of participants; future research may increase the pool of participants
to include senior leadership, employees, and nonsupervisory managers. I recommend
increasing the pool of participants by conducting a multiple case study to investigate
compliance strategies.
The second recommendation is to perform a quantitative or mixed method study.
Researchers use the quantitative method for data collection to test hypothesis or analyze
data using statistical forms, and the results are generalizable (Brockington, 2014).
Researchers can investigate relationships between financial indicators, and how the
indicators influence regulatory compliance and to examine the impact of regulatory
compliance on revenue or other financial indicators. The current study is an exploratory
study providing only in-depth information about the lived experience. Conducting a
quantitative study could generate results that might lead to the generalization findings.
Future research in these areas might increase existing literature in regulatory compliance,
especially among African countries.
Reflections
During the DBA study, I learned the importance of steadfastness and resolved to
complete a task in the face of huge challenges from across the board. The program
enhanced my confidence in the handling life-changing situations because the research
phase of the program built my inner strength and tenacity to accomplish a goal. The
challenges include issues relating to proposal development, finding the right research
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establishment, and managing access to research participants. Within this period, I relied
on networking to secure the research establishment and access to research participants; I
fully appreciate the importance of networking to achieve desired goals. Owing to the
nature of the topic and the location of the research establishment, it was a burden to gain
access to the establishment and participants and use of networking made this study
possible.
Upon selecting the research establishment and research participants, I strived to
minimize bias and personal errors right from the design of the research question and
interview questions to obtain as much lived information from research participants. The
in-depth review of the literature honed my skills in the development of the appropriate
interview questions. In addition, I minimized bias by adhering to the interview protocol.
Before this research study, my research was science-based; as such, I had no
experience about research in management or conducting research interviews and was not
involved in the interaction with the leadership of a corporate organization. The
experience that I gained in this study provided me a new academic vista and prism due to
the opportunity of interacting with professionals in the field and learning their lived
experiences with the research topic. This study exposed me to successful business
practices relative to regulatory compliance with the chosen location. Gaining insight into
the strategies used for compliance offered me the opportunity to compare what I learned
from the study with my experience about the topic in developed nations. I am now more
attuned and have the requisite knowledge to discuss and contribute topics relating to
regulatory compliance in the pharmaceutical industry in Nigeria, including their
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regulatory framework, regulatory agencies, and stakeholders in the pharmaceutical
industry in Nigeria. I will publish the findings of this study in the related or related
professional and academic journals and publications as a contribution to the body of
knowledge.
Conclusion
Ding et al. (2015) argued that compliance with regulation is critical to business
performance, while Page et al. (2015) argued that noncompliance with regulation has
become a challenge to managers. However, only a few studies exist on pharmaceutical
companies’ compliance with regulatory requirements in the Sub-Saharan region
(Olugbenga, 2013). Business Monitor International (2016) reported that Nigeria has a
poor pharmaceutical regulatory environment; as such having insight into the strategies
used by successful companies under such regulatory environment is an important
contribution to knowledge and pharmaceutical business performance. Evaluation of
business compliance under unstable business conditions such as the dynamic regulatory
environment using complexity leadership theory is a plausible approach to understand
how leaders adapt to the changes in the regulatory environment.
The research question addressed the strategies that managers used to ensure
compliance with regulatory requirements. Using CLT, I explored the strategies used by
managers to ensure compliance with regulations. Based on participants’ responses and
data analysis, I found that the establishment of a regulatory affairs unit and engaged
leadership enhanced regulatory compliance. Similarly, the hiring of qualified employees
and their compliance training learning improved compliance with regulatory
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requirements. Furthermore, having strategies to navigate through barriers to enhance
regulatory compliance. All participants emphasized the importance of compliance with
regulatory requirements as part of the availability of products and business success. The
results of this study underscore the critical importance effective regulatory compliance
strategies to the overall success of a pharmaceutical company.
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Appendix A: Interview Protocol
Interview Protocol
What I will do

script

Introduce the interview and set the

I am a student at Walden University pursuing

stage

my Doctor of Business Administration degree
specializing in Technology Entrepreneurship. I
am conducting a research study for my
dissertation entitled “Strategies for Compliance
with Government Regulations in a
Pharmaceutical Company ".
The purpose of this qualitative single case
study is to explore the strategies used by leaders
in pharmaceutical companies to adapt to
regulatory requirements. Management approval
for data collection will be sought, and your
participation in this study is entirely voluntary,
you can withdraw from participating at any
point of the data collection process.



Watch for non-verbal queues



Paraphrase as needed

1. What is your role in ensuring
compliance with government
regulations in your company?
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Ask follow-up probing questions
to get more in-depth

2. What strategies do you use to
prevent noncompliance with
government regulations?
3. How do you communicate
regulatory requirements within your
company?
4. What specific strategies do you use
to ensure regulatory compliance?
5. What challenges do you encounter in
implementing strategies for
compliance with regulatory
requirements?
6. How do you address the challenges
to the implementation of strategies
for noncompliance to government
regulations?
7. How do you assess the effectiveness
of your strategies to prevent
noncompliance
8. What other relevant information
about compliance with regulatory
requirements can you provide?
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Wrap up interview thanking
participant

Thank you for your time and consideration, do
you have any additional questions or
comments?

Inform participants about transcript
review

I would like to send you the transcript of this
recorded interview; can you provide two dates
and times you are available next week?

Follow–up Transcript Review

Introduce follow-up
interview

1. I prepared verbatim transcripts of recorded
interviews
2. Verbatim transcript sent by email to each participant
to review
3. Confirmation/correction of verbatim transcript by
participants
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Appendix B: Invitation Letter
Date:
Re: Doctoral Research Study Invitation
Dear ……..,
I am a student at Walden University pursuing my Doctor of Business
Administration degree specializing in Technology Entrepreneurship. I am conducting a
research study for my dissertation entitled “Strategies for Compliance with Government
Regulations in a Pharmaceutical Company”.
The purpose of this qualitative single case study is to explore strategies that
managers in pharmaceutical companies use to ensure compliance with regulatory
requirements. Management approval for data collection will be sought, and your
participation in this study is entirely voluntary, you can withdraw from participating at
any point of the data collection process.
Participants in this study are not likely to benefit personally or financially by
participating, but participation has the potential for improved abilities of managers to
ensure compliance in a regulated environment, which might lead to increased access,
availability, and affordability of pharmaceutical products by individuals with limited
access to good healthcare.
The research will be conducted in by accordance with Walden University and
HHS guidelines on ethical research. All participants and organizations will be kept
confidential. Interested companies will be credited if they so desire in the final report.
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Please review the consent form attached and if you accept this invitation to
participate in the data collection phase of this study, please
Please do not hesitate to contact me if you have any question or concerns.
Kind regards,

Charles Jagun, Doctoral Research Student
Walden University
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